The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Any fatty acid containing more than one double bond. Acids in this group are reported to have cardioprotective effects; and levels are lowered in chronic fatigue syndrome.
[Food Preservatives results in increased abundance of Sorbic Acid] which results in increased expression of IFNG mRNA [Fructose co-treated with Sorbic Acid] results in increased expression of IFNG protein
[Food Preservatives results in increased abundance of Sorbic Acid] which results in increased expression of IL10 mRNA [Fructose co-treated with Sorbic Acid] results in increased expression of IL10 protein
[Food Preservatives results in increased abundance of Sorbic Acid] which results in increased expression of IL6 mRNA [Fructose co-treated with Sorbic Acid] results in increased expression of IL6 protein
[Food Preservatives results in increased abundance of Sorbic Acid] which results in increased expression of TNF mRNA [Fructose co-treated with Sorbic Acid] results in increased expression of TNF protein Sorbic Acid results in increased expression of TNF mRNA
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in decreased expression of ALOX15 mRNA]]
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid results in decreased expression of ALOX5 protein 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[[Dietary Fats co-treated with Cholesterol, Dietary] results in increased susceptibility to Silver Compounds] which results in decreased expression of ALOX5 mRNA]
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in increased expression of CCL2 mRNA]]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in increased expression of CCL2 protein]]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Silver Compounds results in increased susceptibility to [Dietary Fats co-treated with Cholesterol, Dietary]] which results in increased expression of CCL2 mRNA]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Silver Compounds results in increased susceptibility to [Dietary Fats co-treated with Cholesterol, Dietary]] which results in increased expression of CCL2 protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Silver Compounds results in increased expression of CCL2 mRNA]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Silver Compounds results in increased expression of CCL2 protein]
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in increased expression of CXCL2 mRNA]]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in increased expression of CXCL2 protein]]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Silver Compounds results in increased susceptibility to [Dietary Fats co-treated with Cholesterol, Dietary]] which results in increased expression of CXCL2 mRNA]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Silver Compounds results in increased susceptibility to [Dietary Fats co-treated with Cholesterol, Dietary]] which results in increased expression of CXCL2 protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Silver Compounds results in increased expression of CXCL2 mRNA]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Silver Compounds results in increased expression of CXCL2 protein]; [Silver Compounds results in increased susceptibility to 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid] which results in increased expression of CXCL2 mRNA
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in increased expression of IL6 mRNA]]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in increased expression of IL6 protein]]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Silver Compounds results in increased susceptibility to [Dietary Fats co-treated with Cholesterol, Dietary]] which results in increased expression of IL6 mRNA]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Silver Compounds results in increased susceptibility to [Dietary Fats co-treated with Cholesterol, Dietary]] which results in increased expression of IL6 protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Silver Compounds results in increased expression of IL6 mRNA]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Silver Compounds results in increased expression of IL6 protein]
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein]
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid results in decreased secretion of TNF protein
docosapentaenoic acid results in decreased expression of PTGS2 protein docosapentaenoic acid inhibits the reaction [Dimethoate results in increased expression of PTGS2 protein]
[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA; [[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 protein; [Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid; cinnamyl-3,4-dihydroxycyanocinnamate inhibits the reaction [[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA]; Masoprocol inhibits the reaction [[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA] ALOX15 protein results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid ALOX15 protein results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid
[benoxaprofen results in decreased activity of ALOX5 protein] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid; [Masoprocol results in decreased activity of ALOX5 protein] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid; [RS 43179 results in decreased activity of ALOX5 protein] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid; [tenidap results in decreased activity of ALOX5 protein] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid
APP protein modified form results in increased secretion of 15-hydroxy-5,8,11,13-eicosatetraenoic acid CNB 001 inhibits the reaction [APP protein modified form results in increased secretion of 15-hydroxy-5,8,11,13-eicosatetraenoic acid]; Dronabinol inhibits the reaction [APP protein modified form results in increased secretion of 15-hydroxy-5,8,11,13-eicosatetraenoic acid]; L 685458 inhibits the reaction [APP protein modified form results in increased secretion of 15-hydroxy-5,8,11,13-eicosatetraenoic acid]
15-hydroxy-5,8,11,13-eicosatetraenoic acid promotes the reaction [EGF protein affects the localization of PRKCA protein] EGF protein results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of IL1B protein IL1B protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; IL1B protein affects the reaction [TNF protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]]; TNF protein affects the reaction [IL1B protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]]
[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA; [[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 protein; cinnamyl-3,4-dihydroxycyanocinnamate inhibits the reaction [[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA]; Masoprocol inhibits the reaction [[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA] 15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the activity of KCNA5 protein
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein [parthenolide co-treated with artemisinin co-treated with Quercetin] inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; artemisinin inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; IL1B protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; IL1B protein affects the reaction [TNF protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]]; parthenolide inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; Quercetin inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; SB 203580 inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; TNF protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; TNF protein affects the reaction [IL1B protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]]
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased activity of NFKB1 protein 15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the localization of NFKB1 protein artemisinin inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the localization of NFKB1 protein]
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased phosphorylation of and results in increased degradation of NFKBIA protein; calphostin C inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased phosphorylation of and results in increased degradation of NFKBIA protein] 15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased phosphorylation of and results in increased degradation of NFKBIA protein; Quercetin inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased phosphorylation of and results in increased degradation of NFKBIA protein]
15-hydroxy-5,8,11,13-eicosatetraenoic acid promotes the reaction [EGF protein affects the localization of PRKCA protein]; 15-hydroxy-5,8,11,13-eicosatetraenoic acid promotes the reaction [HGF protein affects the localization of PRKCA protein] calphostin C inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased activity of PRKCA protein] 15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the localization of PRKCA protein
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased activity of RELA protein artemisinin inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the localization of RELA protein]
IL1B protein affects the reaction [TNF protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]]; TNF protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; TNF protein affects the reaction [IL1B protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]] 15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of TNF protein
TRPM6 protein affects the reaction [1-stearoyl-2-arachidonoylglycerol results in increased transport of Barium]; TRPM6 protein affects the reaction [1-stearoyl-2-arachidonoylglycerol results in increased transport of Calcium]
12-HPETE inhibits the reaction [Sodium Salicylate inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid]]; 12-HPETE inhibits the reaction [Sodium Salicylate results in decreased activity of PTGS2 protein]
[PTGS1 protein results in increased metabolism of Arachidonic Acid] which results in increased chemical synthesis of 12-hydroxy-5,8,10-heptadecatrienoic acid; arzanol inhibits the reaction [[PTGS1 protein results in increased metabolism of Arachidonic Acid] which results in increased chemical synthesis of 12-hydroxy-5,8,10-heptadecatrienoic acid]
[Sulfasalazine results in decreased activity of TBXAS1 protein] which results in decreased chemical synthesis of 12-hydroxy-5,8,10-heptadecatrienoic acid
[13-hydroperoxy-9,11-octadecadienoic acid co-treated with 2-chloro-5-nitrobenzanilide] results in increased expression of CCL2 mRNA; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with 2-chloro-5-nitrobenzanilide] results in increased expression of CCL2 protein; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with MK-886] results in increased expression of CCL2 mRNA; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with MK-886] results in increased expression of CCL2 protein
[13-hydroperoxy-9,11-octadecadienoic acid co-treated with 2-chloro-5-nitrobenzanilide] results in increased expression of EGR1 mRNA; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with 2-chloro-5-nitrobenzanilide] results in increased expression of EGR1 protein; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with MK-886] results in increased expression of EGR1 mRNA; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with MK-886] results in increased expression of EGR1 protein
14,15-epoxy-5,8,11-eicosatrienoic acid analog results in decreased expression of AGT protein modified form [14,15-epoxy-5,8,11-eicosatrienoic acid analog results in increased cleavage of AGT protein modified form] which results in increased abundance of angiotensin I (1-7) 14,15-epoxy-5,8,11-eicosatrienoic acid analog inhibits the reaction [REN2 protein results in increased expression of AGT protein modified form]
[Arsenites results in increased expression of and results in increased activity of EPHX2 protein] which results in decreased abundance of 14,15-epoxy-5,8,11-eicosatrienoic acid; [Mercuric Chloride results in increased expression of and results in increased activity of EPHX2 protein] which results in decreased abundance of 14,15-epoxy-5,8,11-eicosatrienoic acid EPHX2 gene mutant form results in increased abundance of 14,15-epoxy-5,8,11-eicosatrienoic acid
TGFB1 protein results in decreased secretion of 14,15-epoxy-5,8,11-eicosatrienoic acid 12-(3-adamantan-1-ylureido)dodecanoic acid inhibits the reaction [TGFB1 protein results in decreased secretion of 14,15-epoxy-5,8,11-eicosatrienoic acid]
15-keto-5,8,11,13-eicosatetraenoic acid results in decreased expression of TNF mRNA 15-keto-5,8,11,13-eicosatetraenoic acid inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]
glyceryl 2-arachidonate results in increased expression of ACTA2 mRNA Acetaldehyde promotes the reaction [glyceryl 2-arachidonate results in increased expression of ACTA2 mRNA]
[[APOE protein affects the susceptibility to [Cholesterol, Dietary co-treated with Dietary Fats]] which affects the susceptibility to JZL 184] which affects the abundance of glyceryl 2-arachidonate
glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB1 protein]; GRK2 protein promotes the reaction [glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]]
[GRK2 protein co-treated with glyceryl 2-arachidonate] affects the reaction [CNR1 protein affects the localization of ARRB2 protein]; [GRK2 protein co-treated with glyceryl 2-arachidonate] promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; glyceryl 2-arachidonate promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]
glyceryl 2-arachidonate results in increased expression of ATF4 mRNA iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased expression of ATF4 mRNA]
CES1 protein results in increased hydrolysis of glyceryl 2-arachidonate [CES1 protein results in increased hydrolysis of glyceryl 2-arachidonate] which results in increased chemical synthesis of Arachidonic Acid
CES2 protein results in increased hydrolysis of glyceryl 2-arachidonate [CES2 protein results in increased hydrolysis of glyceryl 2-arachidonate] which results in increased chemical synthesis of Arachidonic Acid
[CNR1 protein affects the susceptibility to Chlorpyrifos] which affects the hydrolysis of glyceryl 2-arachidonate; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7B1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; CNR1 protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]] glyceryl 2-arachidonate results in increased expression of CNR1 mRNA [GRK2 protein co-treated with glyceryl 2-arachidonate] affects the reaction [CNR1 protein affects the localization of ARRB2 protein]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA]; glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]; glyceryl 2-arachidonate promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]; GRK2 protein promotes the reaction [glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]] Acetaldehyde promotes the reaction [glyceryl 2-arachidonate results in increased expression of CNR1 mRNA]; Nitroglycerin affects the reaction [glyceryl 2-arachidonate affects the activity of CNR1 protein]
[GRK2 protein co-treated with glyceryl 2-arachidonate] promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; [SR 144528 binds to and results in increased activity of CNR2 protein] inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CXCL8 protein]; CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased expression of CXCL8 protein]; CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased transport of Calcium]; glyceryl 2-arachidonate binds to and results in increased activity of CNR2 protein; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB1 protein]; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; Pertussis Toxin inhibits the reaction [CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased transport of Calcium]]; SR 144528 inhibits the reaction [CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased transport of Calcium]] CNR2 gene SNP affects the susceptibility to glyceryl 2-arachidonate
glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]; glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CREB3L3 mRNA]
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]; glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]
glyceryl 2-arachidonate results in increased expression of CYP7B1 mRNA CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7B1 mRNA]
glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA]
1-((fluoro(methyl)phosphoryl)oxy)-3-isopropoxypropan-2-yl oleate inhibits the reaction [DAGLA protein modified form results in increased chemical synthesis of glyceryl 2-arachidonate]
glyceryl 2-arachidonate results in increased expression of DDIT3 mRNA; glyceryl 2-arachidonate results in increased expression of DDIT3 protein iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased expression of DDIT3 mRNA]; iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased expression of DDIT3 protein]
GSK2656157 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of EIF2S1 protein]; iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of EIF2S1 protein]
FABP1 protein affects the abundance of glyceryl 2-arachidonate FABP1 protein affects the reaction [Dronabinol results in increased abundance of glyceryl 2-arachidonate]; FABP1 protein affects the reaction [glyceryl 2-arachidonate results in increased abundance of anandamide]
FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]
[GRK2 protein co-treated with glyceryl 2-arachidonate] affects the reaction [CNR1 protein affects the localization of ARRB2 protein]; [GRK2 protein co-treated with glyceryl 2-arachidonate] promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; GRK2 protein promotes the reaction [glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]]
HCRT protein modified form results in increased chemical synthesis of glyceryl 2-arachidonate 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea inhibits the reaction [HCRT protein modified form results in increased chemical synthesis of glyceryl 2-arachidonate]
glyceryl 2-arachidonate results in decreased expression of IL1B mRNA glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]]
glyceryl 2-arachidonate metabolite inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased secretion of IL2 protein]; T 0070907 inhibits the reaction [glyceryl 2-arachidonate metabolite inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased secretion of IL2 protein]]
glyceryl 2-arachidonate results in decreased expression of IL6 mRNA glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]]
glyceryl 2-arachidonate promotes the reaction [INS1 protein results in increased uptake of Deoxyglucose]; N-(3-methoxyphenyl)-4-chlorocinnamanilide inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [INS1 protein results in increased uptake of Deoxyglucose]]
INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CREB3L3 mRNA]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K1 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K1 protein; U 0126 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K1 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K2 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K2 protein; U 0126 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K2 protein]
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein glyceryl 2-arachidonate results in decreased phosphorylation of MAPK1 protein 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in decreased phosphorylation of MAPK1 protein]; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein glyceryl 2-arachidonate results in decreased phosphorylation of MAPK3 protein 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in decreased phosphorylation of MAPK3 protein]; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]
[Chlorpyrifos results in decreased activity of MGLL protein] which results in increased abundance of glyceryl 2-arachidonate; JZL 184 inhibits the reaction [MGLL protein results in increased hydrolysis of glyceryl 2-arachidonate] MGLL protein affects the abundance of glyceryl 2-arachidonate MGLL protein results in increased degradation of glyceryl 2-arachidonate [FMR1 gene mutant form results in increased activity of MGLL] which results in increased degradation of glyceryl 2-arachidonate; [JZL 184 results in decreased activity of MGLL protein] which results in increased abundance of glyceryl 2-arachidonate; [MJN110 results in decreased activity of MGLL protein] which results in decreased hydrolysis of and results in increased abundance of glyceryl 2-arachidonate MGLL gene mutant form results in increased abundance of glyceryl 2-arachidonate
glyceryl 2-arachidonate affects the localization of PPARA protein [palmidrol co-treated with glyceryl 2-arachidonate] affects the localization of PPARA protein; [palmidrol co-treated with glyceryl 2-arachidonate] affects the reaction [lipopolysaccharide, E. coli O26-B6 affects the localization of PPARA protein]; glyceryl 2-arachidonate affects the reaction [lipopolysaccharide, E. coli O26-B6 affects the localization of PPARA protein]
glyceryl 2-arachidonate metabolite binds to PPARG protein glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in decreased expression of PPARG protein]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]] T 0070907 inhibits the reaction [glyceryl 2-arachidonate metabolite results in increased expression of PPARG mRNA]
PTGS2 protein results in increased metabolism of glyceryl 2-arachidonate 2-chloro-5-nitrobenzanilide inhibits the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; CNR1 protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; rimonabant inhibits the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]] glyceryl 2-arachidonate inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased expression of PTGS2 mRNA]; Ibuprofen inhibits the reaction [PTGS2 protein results in increased metabolism of glyceryl 2-arachidonate]
2-chloro-5-nitrobenzanilide inhibits the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]]; glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]]
glyceryl 2-arachidonate results in decreased expression of TNF mRNA glyceryl 2-arachidonate inhibits the reaction [[Serotonin co-treated with Dextran Sulfate] results in increased expression of TNF protein]; glyceryl 2-arachidonate inhibits the reaction [amyloid beta-protein (25-35) results in increased expression of TNF protein] glyceryl 2-arachidonate inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein]
glyceryl 2-arachidonate binds to and results in increased activity of TRPV1 protein TRPV1 protein affects the susceptibility to glyceryl 2-arachidonate
20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of ACTA2 mRNA; 20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of ACTA2 protein 20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of ACTA2 mRNA]; 20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of ACTA2 protein]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of ACTA2 mRNA]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of ACTA2 protein]
20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of COL1A1 mRNA]; 20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of COL1A1 protein]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of COL1A1 mRNA]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of COL1A1 protein] 20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of COL1A1 mRNA; 20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of COL1A1 protein
20-hydroxy-5,8,11,14-eicosatetraenoic acid affects the reaction [CYP4A1 protein affects the susceptibility to Phenylephrine]; 20-hydroxy-5,8,11,14-eicosatetraenoic acid inhibits the reaction [DDMS inhibits the reaction [CYP4A1 protein results in increased susceptibility to Phenylephrine]] CYP4A1 protein results in increased chemical synthesis of 20-hydroxy-5,8,11,14-eicosatetraenoic acid
Cyclosporine inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased localization of NFATC4 protein]; Tacrolimus inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased localization of NFATC4 protein]
HET0016 inhibits the reaction [POMC protein affects the abundance of 20-hydroxy-5,8,11,14-eicosatetraenoic acid] POMC protein results in increased abundance of 20-hydroxy-5,8,11,14-eicosatetraenoic acid
20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased phosphorylation of SMAD3 protein]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased phosphorylation of SMAD3 protein]
20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of TGFB1 mRNA]; 20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of TGFB1 protein]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of TGFB1 mRNA]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of TGFB1 protein] 20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of TGFB1 mRNA; 20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of TGFB1 protein
[EPHX3 gene mutant form results in decreased hydrolysis of Epoxy Compounds] results in decreased abundance of [9,10,13-trihydroxy-11-octadecenoic acid binds to Ceramides]; [EPHX3 gene mutant form results in decreased hydrolysis of Epoxy Compounds] which results in decreased chemical synthesis of 9,10,13-trihydroxy-11-octadecenoic acid
eleostearic acid inhibits the reaction [methylmercuric chloride results in decreased activity of CAT protein]; eleostearic acid inhibits the reaction [sodium arsenite results in decreased activity of CAT protein] eleostearic acid results in decreased activity of CAT protein
[trans-10,cis-12-conjugated linoleic acid co-treated with cis-9, trans-11-conjugated linoleic acid] results in decreased phosphorylation of IRS1 protein cis-9, trans-11-conjugated linoleic acid inhibits the reaction [TNF protein results in decreased expression of IRS1 mRNA]
[cis-9, trans-11-conjugated linoleic acid co-treated with trans-10,cis-12-conjugated linoleic acid] results in increased phosphorylation of and results in increased activity of MAP2K1 protein; cis-9, trans-11-conjugated linoleic acid results in increased phosphorylation of and results in increased activity of MAP2K1 protein
[cis-9, trans-11-conjugated linoleic acid co-treated with trans-10,cis-12-conjugated linoleic acid] results in increased phosphorylation of and results in increased activity of MAP2K3 protein; cis-9, trans-11-conjugated linoleic acid results in increased phosphorylation of and results in increased activity of MAP2K3 protein
[trans-10,cis-12-conjugated linoleic acid co-treated with cis-9, trans-11-conjugated linoleic acid] results in increased expression of PPARA mRNA; [trans-10,cis-12-conjugated linoleic acid co-treated with cis-9, trans-11-conjugated linoleic acid] results in increased expression of PPARA protein
[cis-9, trans-11-conjugated linoleic acid co-treated with trans-10,cis-12-conjugated linoleic acid] results in increased expression of PPARG protein; bisphenol A diglycidyl ether inhibits the reaction [[cis-9, trans-11-conjugated linoleic acid co-treated with trans-10,cis-12-conjugated linoleic acid] results in increased expression of PPARG protein]
cis-9, trans-11-conjugated linoleic acid results in increased expression of SLC2A4 protein cis-9, trans-11-conjugated linoleic acid inhibits the reaction [TNF protein results in decreased expression of SLC2A4 mRNA]
cis-9, trans-11-conjugated linoleic acid inhibits the reaction [TNF protein results in decreased expression of IRS1 mRNA]; cis-9, trans-11-conjugated linoleic acid inhibits the reaction [TNF protein results in decreased expression of SLC2A4 mRNA] cis-9, trans-11-conjugated linoleic acid affects the expression of TNF mRNA
arachidonyltrifluoromethane inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]
arachidonyltrifluoromethane results in increased secretion of INS protein arachidonyltrifluoromethane inhibits the reaction [Glucose results in increased secretion of INS protein]
arachidonyltrifluoromethane inhibits the reaction [NRG1 protein alternative form results in increased phosphorylation of and results in increased activity of MAPK1 protein]
arachidonyltrifluoromethane inhibits the reaction [NRG1 protein alternative form results in increased phosphorylation of and results in increased activity of MAPK3 protein]
arachidonyltrifluoromethane inhibits the reaction [NRG1 protein alternative form results in increased phosphorylation of and results in increased activity of MAPK1 protein]; arachidonyltrifluoromethane inhibits the reaction [NRG1 protein alternative form results in increased phosphorylation of and results in increased activity of MAPK3 protein]
arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of PLA2G4A protein] arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PLA2G4A mRNA]
arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of PTGS2 protein]; arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA]; arachidonyltrifluoromethane promotes the reaction [Nifedipine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA]]
arachidonyltrifluoromethane inhibits the reaction [S100A11 mutant form results in increased susceptibility to Cisplatin]; arachidonyltrifluoromethane inhibits the reaction [S100A11 mutant form results in increased susceptibility to Oxaliplatin]
arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of VEGFA mRNA] arachidonyltrifluoromethane promotes the reaction [Nifedipine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of VEGFA mRNA]]
[caffeic acid results in decreased activity of ALOX15 protein] which results in decreased chemical synthesis of 13-hydroxy-9,11-octadecadienoic acid; [caffeic acid results in decreased activity of ALOX15 protein] which results in increased abundance of 13-hydroxy-9,11-octadecadienoic acid; [Masoprocol results in decreased activity of ALOX15 protein] which results in increased abundance of 13-hydroxy-9,11-octadecadienoic acid; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased expression of ALOX15 protein] which results in increased chemical synthesis of 13-hydroxy-9,11-octadecadienoic acid; [Sulindac results in increased expression of ALOX15 protein] which results in increased chemical synthesis of 13-hydroxy-9,11-octadecadienoic acid; [Vorinostat results in increased expression of ALOX15 protein] which results in increased abundance of 13-hydroxy-9,11-octadecadienoic acid
alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of CCL2 protein]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of CCL2 mRNA]]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of CCL2 protein]]; Particulate Matter inhibits the reaction [alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of CCL2 protein]]
CYP2C19 protein results in increased metabolism of [alpha-Linolenic Acid co-treated with NADP] alpha-Linolenic Acid results in decreased activity of CYP2C19 protein
[[alpha-Linolenic Acid co-treated with Estradiol] results in increased expression of FADS1 mRNA] which affects the abundance of Fatty Acids, Unsaturated; [[alpha-Linolenic Acid co-treated with Testosterone] results in decreased expression of FADS1 mRNA] which affects the abundance of Fatty Acids, Unsaturated; [alpha-Linolenic Acid co-treated with Estradiol] results in increased expression of FADS1 mRNA; [alpha-Linolenic Acid co-treated with Testosterone] results in decreased expression of FADS1 mRNA; fulvestrant inhibits the reaction [[alpha-Linolenic Acid co-treated with Estradiol] results in increased expression of FADS1 mRNA]
alpha-Linolenic Acid results in increased expression of GSTA1 mRNA NFE2L2 protein promotes the reaction [alpha-Linolenic Acid results in increased expression of GSTA1 mRNA]
alpha-Linolenic Acid results in increased expression of HMOX1 mRNA alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [Cholesterol results in increased expression of HMOX1 mRNA]]
alpha-Linolenic Acid inhibits the reaction [[Cholesterol co-treated with Particulate Matter] results in increased expression of IFNG protein]; alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of IFNG mRNA]; alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of IFNG protein]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of IFNG mRNA]]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of IFNG protein]]
[Eicosapentaenoic Acid co-treated with Docosahexaenoic Acids co-treated with alpha-Linolenic Acid] results in increased expression of IL1B protein alpha-Linolenic Acid inhibits the reaction [[Cholesterol co-treated with Particulate Matter] results in increased expression of IL1B protein]
alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of IL6 mRNA]; alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of IL6 protein]; alpha-Linolenic Acid inhibits the reaction [Cholesterol promotes the reaction [Particulate Matter results in increased expression of IL6 protein]]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of IL6 mRNA]]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of IL6 protein]]; Particulate Matter inhibits the reaction [alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of IL6 mRNA]]
NFE2L2 protein promotes the reaction [alpha-Linolenic Acid results in increased expression of CYP2A6 mRNA]; NFE2L2 protein promotes the reaction [alpha-Linolenic Acid results in increased expression of CYP2A6 protein]; NFE2L2 protein promotes the reaction [alpha-Linolenic Acid results in increased expression of GSTA1 mRNA] alpha-Linolenic Acid inhibits the reaction [Cholesterol promotes the reaction [Particulate Matter results in increased expression of NFE2L2 mRNA]]; alpha-Linolenic Acid inhibits the reaction [Cholesterol results in increased expression of NFE2L2 mRNA]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [Cholesterol results in increased expression of NFE2L2 mRNA]]
alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of NOS2 mRNA]; alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of NOS2 protein]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of NOS2 mRNA]]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of NOS2 protein]]; Particulate Matter inhibits the reaction [alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of NOS2 mRNA]]; Particulate Matter inhibits the reaction [alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of NOS2 protein]]
alpha-Linolenic Acid inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein] alpha-Linolenic Acid binds to NR1H4 protein
alpha-Linolenic Acid binds to and results in increased activity of PPARA protein PPARA protein affects the abundance of alpha-Linolenic Acid alpha-Linolenic Acid results in increased expression of PPARA mRNA alpha-Linolenic Acid binds to and results in increased activity of PPARA protein; Calcitriol promotes the reaction [alpha-Linolenic Acid results in increased expression of PPARA mRNA] alpha-Linolenic Acid binds to and results in increased activity of PPARA protein; Diethylhexyl Phthalate inhibits the reaction [PPARA protein affects the abundance of alpha-Linolenic Acid]
alpha-Linolenic Acid results in increased expression of PPARD mRNA; Calcitriol results in increased expression of [alpha-Linolenic Acid results in increased expression of PPARD mRNA] alpha-Linolenic Acid binds to and results in increased activity of PPARB protein
alpha-Linolenic Acid results in increased expression of PPARG mRNA alpha-Linolenic Acid results in increased activity of PPARG protein alpha-Linolenic Acid binds to and results in increased activity of PPARG protein
alpha-Linolenic Acid results in increased expression of PTGS2 mRNA alpha-Linolenic Acid results in increased expression of PTGS2 protein alpha-Linolenic Acid results in decreased expression of PTGS2 mRNA
alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of TNF mRNA]; alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of TNF protein]; alpha-Linolenic Acid inhibits the reaction [Cholesterol promotes the reaction [Particulate Matter results in increased expression of TNF protein]]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of TNF mRNA]]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of TNF protein]]; Particulate Matter inhibits the reaction [alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of TNF protein]]
alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of VCAM1 mRNA]; alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of VCAM1 protein]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of VCAM1 mRNA]]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of VCAM1 protein]]; Particulate Matter inhibits the reaction [alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of VCAM1 protein]]
alpha-Linolenic Acid results in increased expression of VDR mRNA [Calcitriol co-treated with alpha-Linolenic Acid] results in increased expression of VDR mRNA
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in decreased expression of ABCG2 mRNA]; anandamide affects the reaction [O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate affects the expression of ABCG2 mRNA]; anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]; Colforsin inhibits the reaction [anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]]; iodopravadoline inhibits the reaction [anandamide results in decreased expression of ABCG2 mRNA] anandamide results in decreased expression of ABCG2 mRNA; anandamide results in decreased expression of ABCG2 protein
anandamide results in decreased susceptibility to APP protein APP protein results in decreased metabolism of anandamide APP protein results in decreased abundance of anandamide
anandamide results in increased cleavage of CASP3 protein 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [anandamide results in increased cleavage of CASP3 protein]
anandamide affects the activity of CNR1 protein CNR1 protein results in increased susceptibility to anandamide anandamide results in decreased expression of CNR1 protein anandamide binds to CNR1 protein anandamide results in increased activity of CNR1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased activity of CNR1]; anandamide promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]; CNR1 affects the reaction [TRPV1 affects the susceptibility to anandamide]; Pertussis Toxin inhibits the reaction [anandamide results in increased activity of CNR1]; Rimonabant inhibits the reaction [anandamide results in increased activity of CNR1] [anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]; [CNR1 protein affects the susceptibility to Chlorpyrifos] which affects the hydrolysis of anandamide; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Rimonabant inhibits the reaction [[anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased transport of Nitric Oxide]]; SR 144528 inhibits the reaction [[anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased transport of Nitric Oxide]]
anandamide affects the activity of CNR2 protein anandamide binds to CNR2 protein anandamide binds to and results in increased activity of CNR2 protein; CNR2 affects the reaction [TRPV1 affects the susceptibility to anandamide]
anandamide inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]; Colforsin inhibits the reaction [anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]] anandamide results in decreased phosphorylation of CREB1 protein
cannabichromene inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; Cannabidiol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; cannabigerol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; Cannabinol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; delta-8-tetrahydrocannabinol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; Dronabinol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]
anandamide results in increased expression of DDIT3 mRNA; anandamide results in increased expression of DDIT3 protein 4-phenylbutyric acid inhibits the reaction [anandamide results in increased expression of DDIT3 protein]; 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [anandamide results in increased expression of DDIT3 protein]
anandamide results in increased phosphorylation of EIF2S1 protein 4-phenylbutyric acid inhibits the reaction [anandamide results in increased phosphorylation of EIF2S1 protein]
FAAH results in increased degradation of anandamide FAAH gene mutant form results in increased susceptibility to anandamide FAAH gene mutant form results in decreased metabolism of anandamide FAAH protein results in increased degradation of anandamide [Chlorpyrifos results in decreased activity of FAAH protein] which results in increased abundance of anandamide; [cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester results in decreased activity of FAAH protein] which results in increased abundance of anandamide; [Lipopolysaccharides results in decreased expression of FAAH protein] which results in increased abundance of anandamide; FAAH protein results in increased metabolism of and results in decreased activity of anandamide; Nitroglycerin promotes the reaction [FAAH protein results in increased degradation of anandamide]; Silybin inhibits the reaction [FAAH protein results in increased metabolism of and results in decreased activity of anandamide] anandamide affects the expression of FAAH protein [cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester results in decreased activity of FAAH protein] which results in decreased metabolism of anandamide; [nimesulide results in decreased expression of PTGS2] promotes the reaction [FAAH affects the metabolism of anandamide]; [PF 3845 results in decreased activity of FAAH protein] which results in decreased metabolism of anandamide; Rimonabant inhibits the reaction [FAAH gene mutant form results in increased susceptibility to anandamide]
11-hydroxy-delta(9)-tetrahydrocannabinol inhibits the reaction [anandamide analog binds to FABP1 protein]; Dronabinol inhibits the reaction [anandamide analog binds to FABP1 protein] FABP1 protein affects the abundance of anandamide FABP1 protein affects the reaction [Dronabinol results in increased abundance of anandamide]; FABP1 protein affects the reaction [glyceryl 2-arachidonate results in increased abundance of anandamide]
anandamide inhibits the reaction [Nitroglycerin results in increased expression of FOS protein]; capsazepine inhibits the reaction [anandamide results in increased expression of FOS protein]; resiniferatoxin inhibits the reaction [anandamide results in increased expression of FOS protein] anandamide results in increased expression of FOS; anandamide results in increased expression of FOS protein
anandamide affects the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of TNF]; anandamide inhibits the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of IL1B]
[OMDM-1 cpd co-treated with anandamide] inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein]; anandamide inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein]
anandamide inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; anandamide inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]] anandamide inhibits the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of IL1B]; anandamide promotes the reaction [IL1B protein results in increased expression of F3 protein]
LEP protein results in decreased abundance of anandamide Dietary Fats inhibits the reaction [LEP protein results in decreased abundance of anandamide] LEP protein results in decreased activity of anandamide LEP protein results in decreased transport of anandamide
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein; U 0126 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein; U 0126 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein]
anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein] anandamide results in increased phosphorylation of MAPK1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; AM 251 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; Hydrogen Peroxide promotes the reaction [anandamide results in increased phosphorylation of MAPK1 protein]; JTE 907 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Pertussis Toxin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; wortmannin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein] 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; Rimonabant inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]
anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein] anandamide results in increased phosphorylation of MAPK3 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; AM 251 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; Hydrogen Peroxide promotes the reaction [anandamide results in increased phosphorylation of MAPK3 protein]; JTE 907 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Pertussis Toxin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; wortmannin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein] 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; rimonabant inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]
anandamide inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; anandamide inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]
[nimesulide results in decreased expression of PTGS2] which results in increased activity of anandamide anandamide results in increased expression of PTGS2 mRNA; anandamide results in increased expression of PTGS2 protein PTGS2 results in increased metabolism of anandamide [nimesulide results in decreased expression of PTGS2] promotes the reaction [FAAH affects the metabolism of anandamide]
anandamide inhibits the reaction [thrombin receptor-activating peptide SFLLRNPNDKY results in increased expression of SELP protein] anandamide results in increased expression of SELP protein
anandamide results in increased expression of TIMP1 mRNA N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [anandamide results in increased expression of TIMP1 mRNA]
anandamide inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein] anandamide inhibits the reaction [[Serotonin co-treated with Dextran Sulfate] results in increased expression of TNF protein] TNF protein results in increased abundance of anandamide anandamide affects the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of TNF]
3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [anandamide promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; anandamide binds to and results in increased activity of TRPV1 protein; capsazepine inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; CNR1 affects the reaction [TRPV1 affects the susceptibility to anandamide]; CNR2 affects the reaction [TRPV1 affects the susceptibility to anandamide]; Egtazic Acid inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; methyl arachidonylfluorophosphonate promotes the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; N-(2-methyl-3-hydroxyphenyl)-5,8,11,14-eicosatetraenamide inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; Nitroprusside promotes the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; Phenylmethylsulfonyl Fluoride promotes the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; rimonabant inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein] TRPV1 protein results in increased susceptibility to anandamide anandamide results in increased activity of TRPV1 protein 3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [anandamide promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; anandamide binds to and results in increased activity of TRPV1 protein; bisindolylmaleimide inhibits the reaction [anandamide results in increased activity of TRPV1 protein]; Eicosapentaenoic Acid inhibits the reaction [anandamide results in increased activity of TRPV1 protein]; Tetradecanoylphorbol Acetate promotes the reaction [anandamide results in increased activity of TRPV1 protein] anandamide binds to TRPV1 protein
Arachidonic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; Arachidonic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Phospholipids]] Arachidonic Acid results in increased degradation of ABCA1 protein
Eicosapentaenoic Acid inhibits the reaction [AGT protein results in increased metabolism of and results in increased abundance of Arachidonic Acid]; Quinacrine inhibits the reaction [AGT protein results in increased metabolism of and results in increased abundance of Arachidonic Acid]
Arachidonic Acid results in increased phosphorylation of AKT1 protein aristolochic acid I inhibits the reaction [Arachidonic Acid results in increased phosphorylation of AKT1 protein]
ALOX15 protein affects the metabolism of Arachidonic Acid [ALOX15 protein affects the metabolism of Arachidonic Acid] which affects the susceptibility to Acetylcholine; [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of 11,12,15-trihydroxyeicosatrienoic acid; [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of 11,14,15-trihydroxyeicosa-5,8,12-trienoic acid; [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of 15-hydroxy-11,12-epoxyeicosatrienoic acid; [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid; [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of 6-Ketoprostaglandin F1 alpha; [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of Dinoprostone; ALOX15 protein results in increased metabolism of and affects the susceptibility to Arachidonic Acid ALOX15 protein results in increased metabolism of Arachidonic Acid [IL4 protein co-treated with Arachidonic Acid] results in increased activity of ALOX15 protein; [IL4 protein co-treated with Arachidonic Acid] results in increased expression of ALOX15 mRNA
[sodium arsenite co-treated with Platelet Activating Factor co-treated with Arachidonic Acid] results in increased phosphorylation of and results in increased activity of ALOX5 protein; [Sorbitol co-treated with Calcimycin co-treated with Arachidonic Acid] affects the localization of ALOX5 protein; [TP53 protein results in increased expression of ALOX5 mRNA] which results in increased metabolism of Arachidonic Acid; [zileuton results in decreased activity of ALOX5 protein] which affects the abundance of Arachidonic Acid; [zileuton results in decreased activity of ALOX5 protein] which results in decreased susceptibility to Arachidonic Acid; Arachidonic Acid inhibits the reaction [L 708714 binds to ALOX5 protein]; CJ 13610 inhibits the reaction [ALOX5 protein results in increased metabolism of Arachidonic Acid]; zileuton inhibits the reaction [ALOX5 protein results in increased metabolism of Arachidonic Acid]
Arachidonic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; Arachidonic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Phospholipids]] Arachidonic Acid results in decreased expression of APOA1 mRNA
APOE gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]; Aspirin inhibits the reaction [APOE gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]]; dazoxiben inhibits the reaction [APOE gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]]; tempol inhibits the reaction [APOE gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]] Aspirin inhibits the reaction [APOE gene mutant form results in decreased susceptibility to Arachidonic Acid]; dazoxiben inhibits the reaction [APOE gene mutant form results in decreased susceptibility to Arachidonic Acid]; Indomethacin promotes the reaction [APOE gene mutant form results in decreased susceptibility to Arachidonic Acid]; tempol inhibits the reaction [APOE gene mutant form results in decreased susceptibility to Arachidonic Acid]
APP protein modified form results in increased secretion of Arachidonic Acid [1,1,1,2,2-pentafluoro-7-phenylheptan-3-one co-treated with Orlistat] inhibits the reaction [APP protein modified form results in increased secretion of Arachidonic Acid]
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Arachidonic Acid results in increased phosphorylation of ATF2 protein]
[Arachidonic Acid co-treated with Iron] results in increased expression of BAD protein; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of BAD protein]
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]; [Arachidonic Acid co-treated with Iron] results in increased expression of BAX protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]; MAPK14 mutant form inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]; MAPK8 mutant form inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of BAX protein]; pyrazolanthrone inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]
Arachidonic Acid results in decreased expression of BCL2 protein 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; [Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; MAPK14 mutant form inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; MAPK8 mutant form inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; pyrazolanthrone inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; resveratrol inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2 protein]
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein]; [Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2L1 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein]; Drugs, Chinese Herbal inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2L1 protein]; MAPK14 mutant form inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein]; MAPK8 mutant form inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2L1 protein]; pyrazolanthrone inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein]; Resveratrol inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2L1 protein]
Arachidonic Acid results in increased cleavage of BID protein FADD protein promotes the reaction [Arachidonic Acid results in increased cleavage of BID protein]
Arachidonic Acid results in increased activity of CASP3 protein 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Arachidonic Acid results in increased degradation of CASP3 protein alternative form]; [Arachidonic Acid co-treated with Iron] results in decreased expression of CASP3 protein; [Arachidonic Acid co-treated with Iron] results in increased cleavage of CASP3 protein; [Arachidonic Acid co-treated with Iron] results in increased expression of CASP3 protein modified form; Drugs, Chinese Herbal inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased cleavage of CASP3 protein]; FADD protein promotes the reaction [Arachidonic Acid results in increased activity of CASP3 protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased cleavage of CASP3 protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of CASP3 protein modified form]; Resveratrol inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of CASP3 protein]
Arachidonic Acid results in decreased activity of CES1 protein [Arachidonic Acid co-treated with ferric chloride] results in decreased activity of CES1 protein; epigallocatechin gallate inhibits the reaction [[Arachidonic Acid co-treated with ferric chloride] results in decreased activity of CES1 protein]; gallocatechol inhibits the reaction [[Arachidonic Acid co-treated with ferric chloride] results in decreased activity of CES1 protein] [Arachidonic Acid co-treated with ferric chloride] results in decreased activity of CES1 protein; [CES1 protein results in increased hydrolysis of glyceryl 2-arachidonate] which results in increased chemical synthesis of Arachidonic Acid; epigallocatechin gallate inhibits the reaction [[Arachidonic Acid co-treated with ferric chloride] results in decreased activity of CES1 protein]
Arachidonic Acid results in increased phosphorylation of CREB1 protein Ketoconazole inhibits the reaction [Arachidonic Acid results in increased phosphorylation of CREB1 protein]
CYGB protein inhibits the reaction [[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TGFB1 mRNA]; CYGB protein inhibits the reaction [[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TIMP1 mRNA]; CYGB protein results in decreased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]
CYP1A1 protein affects the metabolism of Arachidonic Acid Arachidonic Acid inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]
Arachidonic Acid results in decreased activity of CYP2C19 protein CYP2C19 protein results in increased metabolism of Arachidonic Acid CYP2C19 gene SNP affects the susceptibility to [Adenosine Diphosphate co-treated with Arachidonic Acid]; CYP2C19 protein results in increased metabolism of [Arachidonic Acid co-treated with NADP]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; [[Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein] which results in increased expression of KRT18 protein; [[Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein] which results in increased expression of KRT8 protein; [Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein; [CYP2E1 protein co-treated with Arachidonic Acid] results in increased expression of KLF6 protein; [CYP2E1 protein co-treated with Hydrogen Peroxide co-treated with Arachidonic Acid] results in increased expression of KLF6 protein; [CYP2E1 protein co-treated with Vitamin K 3 co-treated with Arachidonic Acid] results in increased expression of KLF6 protein; allyl sulfide inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; allyl sulfide inhibits the reaction [CYP2E1 protein promotes the reaction [Arachidonic Acid results in increased expression of KLF6 mRNA alternative form]]; allyl sulfide inhibits the reaction [CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]]; Arachidonic Acid inhibits the reaction [CYP2E1 protein results in decreased expression of KLF6 mRNA alternative form]; Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA alternative form]; Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]; Cadmium Chloride affects the reaction [CYP2E1 protein results in increased susceptibility to Arachidonic Acid]; CYP2E1 protein promotes the reaction [Arachidonic Acid results in increased expression of KLF6 mRNA alternative form]; CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]; CYP2E1 results in increased susceptibility to [Arachidonic Acid co-treated with Zinc Sulfate]; Ditiocarb inhibits the reaction [CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]]; pyrazolanthrone inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; SB 203580 promotes the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; Vitamin E inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; Vitamin E inhibits the reaction [CYP2E1 protein promotes the reaction [Arachidonic Acid results in increased expression of KLF6 mRNA alternative form]]; Wortmannin inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; Zinc Sulfate inhibits the reaction [CYP2E1 results in increased susceptibility to Arachidonic Acid] CYP2E1 protein affects the hydroxylation of Arachidonic Acid Arachidonic Acid results in decreased activity of CYP2E1 protein
Ketoconazole inhibits the reaction [CYP3A4 protein results in increased metabolism of Arachidonic Acid] Arachidonic Acid results in decreased activity of CYP3A4 protein
5,8,11,14-Eicosatetraynoic Acid inhibits the reaction [Arachidonic Acid results in increased phosphorylation of and results in increased activity of EGFR protein]
FADD protein promotes the reaction [Arachidonic Acid results in increased activity of CASP3 protein]; FADD protein promotes the reaction [Arachidonic Acid results in increased activity of CASP8 protein]; FADD protein promotes the reaction [Arachidonic Acid results in increased cleavage of BID protein]
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein]; Acetylcysteine inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein]; FOS protein affects the reaction [MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein]]; JUN protein affects the reaction [Arachidonic Acid results in increased expression of FAS protein]; MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein] Arachidonic Acid results in increased expression of FAS mRNA; Arachidonic Acid results in increased expression of FAS protein
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein]; Acetylcysteine inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein]; FOS protein affects the reaction [MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein]]; JUN protein affects the reaction [Arachidonic Acid results in increased expression of FASLG protein]; MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein] Arachidonic Acid results in increased expression of FASLG mRNA; Arachidonic Acid results in increased expression of FASLG protein
[Arachidonic Acid co-treated with Quercetin co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in decreased expression of FOS protein; Arachidonic Acid inhibits the reaction [Quercetin results in increased expression of FOS protein]; Flurbiprofen inhibits the reaction [Arachidonic Acid results in increased expression of FOS mRNA]; FOS protein affects the reaction [MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein]]; FOS protein affects the reaction [MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Arachidonic Acid results in increased expression of FOS mRNA] Arachidonic Acid results in decreased phosphorylation of FOS protein
Drugs, Chinese Herbal inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of ALT protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of ALT protein]
[Iodoacetates results in decreased activity of GPX4 protein] which affects the metabolism of Arachidonic Acid; Arachidonic Acid promotes the reaction [Sodium Selenite results in increased expression of and results in increased activity of GPX4 protein]
Arachidonic Acid results in increased expression of HMOX1 mRNA Arachidonic Acid metabolite results in increased expression of HMOX1 mRNA; Arachidonic Acid metabolite results in increased expression of HMOX1 protein NFE2L2 gene mutant form inhibits the reaction [Arachidonic Acid metabolite results in increased expression of HMOX1 protein] HMOX1 protein results in decreased susceptibility to Arachidonic Acid
[Arachidonic Acid results in increased abundance of Dinoprostone] promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]
[IL4 protein co-treated with Arachidonic Acid] results in increased activity of ALOX15 protein; [IL4 protein co-treated with Arachidonic Acid] results in increased expression of ALOX15 mRNA
Arachidonic Acid results in increased secretion of INS protein Arachidonic Acid promotes the reaction [Glucose results in increased secretion of INS protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [Arachidonic Acid results in increased secretion of INS protein]; phenidone promotes the reaction [Arachidonic Acid results in increased secretion of INS protein]
Arachidonic Acid results in increased expression of ITGA2B protein Aspirin inhibits the reaction [Arachidonic Acid results in increased expression of ITGA2B protein]; Glucose inhibits the reaction [Aspirin inhibits the reaction [Arachidonic Acid results in increased expression of ITGA2B protein]]
Aspirin inhibits the reaction [Arachidonic Acid results in increased expression of ITGB3 protein]; Glucose inhibits the reaction [Aspirin inhibits the reaction [Arachidonic Acid results in increased expression of ITGB3 protein]]; Quercetin inhibits the reaction [Arachidonic Acid results in increased expression of ITGB3 protein]
Arachidonic Acid results in increased expression of JUN mRNA Arachidonic Acid results in increased expression of and results in increased phosphorylation of JUN protein; JUN protein affects the reaction [Arachidonic Acid results in increased expression of FAS protein]; JUN protein affects the reaction [Arachidonic Acid results in increased expression of FASLG protein]
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Arachidonic Acid analog results in increased expression of JUNB mRNA] Arachidonic Acid results in increased expression of JUNB mRNA
Arachidonic Acid results in increased expression of KLF6 mRNA; Arachidonic Acid results in increased expression of KLF6 mRNA alternative form; Arachidonic Acid results in increased expression of KLF6 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; [Arachidonic Acid co-treated with Hydrogen Peroxide] results in increased expression of KLF6 protein; [Arachidonic Acid co-treated with SB 203580] results in decreased expression of KLF6 mRNA; [Arachidonic Acid co-treated with Vitamin K 3] results in increased expression of KLF6 protein; [CYP2E1 protein co-treated with Arachidonic Acid] results in increased expression of KLF6 protein; [CYP2E1 protein co-treated with Hydrogen Peroxide co-treated with Arachidonic Acid] results in increased expression of KLF6 protein; [CYP2E1 protein co-treated with Vitamin K 3 co-treated with Arachidonic Acid] results in increased expression of KLF6 protein; allyl sulfide inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; allyl sulfide inhibits the reaction [Arachidonic Acid results in increased expression of KLF6 mRNA alternative form]; allyl sulfide inhibits the reaction [CYP2E1 protein promotes the reaction [Arachidonic Acid results in increased expression of KLF6 mRNA alternative form]]; Arachidonic Acid inhibits the reaction [CYP2E1 protein results in decreased expression of KLF6 mRNA alternative form]; Arachidonic Acid inhibits the reaction [pyrazolanthrone results in decreased expression of KLF6 mRNA]; Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA alternative form]; Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]; CYP2E1 protein promotes the reaction [Arachidonic Acid results in increased expression of KLF6 mRNA alternative form]; pyrazolanthrone inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; SB 203580 promotes the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; Vitamin E inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; Vitamin E inhibits the reaction [CYP2E1 protein promotes the reaction [Arachidonic Acid results in increased expression of KLF6 mRNA alternative form]]; Wortmannin inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]
[[Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein] which results in increased expression of KRT18 protein
[[Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein] which results in increased expression of KRT8 protein
Aspirin inhibits the reaction [LDLR gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]]; dazoxiben inhibits the reaction [LDLR gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]]; LDLR gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]; tempol inhibits the reaction [LDLR gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]] LDLR gene mutant form results in decreased susceptibility to Arachidonic Acid Aspirin inhibits the reaction [LDLR gene mutant form results in decreased susceptibility to Arachidonic Acid]; dazoxiben inhibits the reaction [LDLR gene mutant form results in decreased susceptibility to Arachidonic Acid]; Indomethacin promotes the reaction [LDLR gene mutant form results in decreased susceptibility to Arachidonic Acid]
LIPC gene mutant form results in decreased abundance of Arachidonic Acid [LIPC gene mutant form co-treated with LIPG gene mutant form] results in decreased abundance of Arachidonic Acid
LIPG gene mutant form results in decreased abundance of Arachidonic Acid [LIPC gene mutant form co-treated with LIPG gene mutant form] results in decreased abundance of Arachidonic Acid
FOS protein affects the reaction [MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein]]; FOS protein affects the reaction [MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein]]; MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein]; MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein]
Arachidonic Acid results in increased phosphorylation of MAPK1 protein MAPK1 protein affects the abundance of Arachidonic Acid [Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK1 protein; CYP2C23 mRNA promotes the reaction [[Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK1 protein]; CYP2C23 mRNA promotes the reaction [Arachidonic Acid results in increased phosphorylation of MAPK1 protein]
MAPK14 mutant form inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]; MAPK14 mutant form inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; MAPK14 mutant form inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein] MAPK14 protein promotes the reaction [2,2',4,6-tetrachlorobiphenyl results in increased secretion of Arachidonic Acid]
[Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK3 protein; CYP2C23 mRNA promotes the reaction [[Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK3 protein]; CYP2C23 mRNA promotes the reaction [Arachidonic Acid results in increased phosphorylation of MAPK3 protein] MAPK3 protein affects the abundance of Arachidonic Acid
MAPK8 mutant form inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]; MAPK8 mutant form inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; MAPK8 mutant form inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein]
Arachidonic Acid results in increased phosphorylation of MAPT protein Ro 31-8220 inhibits the reaction [Arachidonic Acid results in increased phosphorylation of MAPT protein]
Arachidonic Acid results in increased secretion of MMP13 protein Isotretinoin inhibits the reaction [Arachidonic Acid results in increased expression of MMP13 mRNA]; Isotretinoin inhibits the reaction [Arachidonic Acid results in increased secretion of MMP13 protein]
Isotretinoin inhibits the reaction [Arachidonic Acid results in increased expression of MMP2 mRNA]; Isotretinoin inhibits the reaction [Arachidonic Acid results in increased secretion of MMP2 protein]
Arachidonic Acid results in increased expression of MMP9 mRNA Isotretinoin inhibits the reaction [Arachidonic Acid results in increased expression of MMP9 mRNA]; Isotretinoin inhibits the reaction [Arachidonic Acid results in increased secretion of MMP9 protein]
Arachidonic Acid results in increased secretion of MPO protein 5-((1,5-bis(4-methoxyphenyl)pyrazol-3-yl)dimethoxymethyl)-2-chlorobenzamide inhibits the reaction [Arachidonic Acid results in increased expression of MPO protein]
Adiponectin inhibits the reaction [Arachidonic Acid results in increased localization of NCF1 protein]; Arachidonic Acid affects the reaction [Zymosan analog affects the localization of NCF1 protein]
NFE2L2 gene mutant form inhibits the reaction [Arachidonic Acid metabolite results in increased expression of HMOX1 protein] Arachidonic Acid metabolite results in increased expression of NFE2L2 protein
Arachidonic Acid results in increased cleavage of and results in increased secretion of NOX1 protein; Cholesterol, LDL affects the reaction [Adiponectin inhibits the reaction [Arachidonic Acid results in increased cleavage of NOX1 protein]]
[NR5A2 gene mutant form results in increased susceptibility to Dietary Fats] which results in decreased abundance of Arachidonic Acid analog NR5A2 gene mutant form results in decreased chemical synthesis of Arachidonic Acid
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Arachidonic Acid results in increased cleavage of PARP1 protein]; [Arachidonic Acid co-treated with Iron] results in increased expression of PARP1 protein modified form; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of PARP1 protein modified form]
AHR affects the reaction [Tetrachlorodibenzodioxin promotes the reaction [PLA2G4A protein results in increased secretion of Arachidonic Acid]]; Dinoprostone promotes the reaction [Arachidonic Acid results in increased expression of PLA2G4A mRNA]; Flurbiprofen inhibits the reaction [Arachidonic Acid results in increased expression of PLA2G4A mRNA] PLA2G4A protein promotes the reaction [2,2',4,6-tetrachlorobiphenyl results in increased secretion of Arachidonic Acid] Arachidonic Acid results in increased expression of PLA2G4A mRNA; Arachidonic Acid results in increased expression of PLA2G4A protein
Arachidonic Acid results in increased expression of PLIN2 mRNA Arachidonic Acid results in increased expression of PLIN2 mRNA; Arachidonic Acid results in increased expression of PLIN2 protein
Arachidonic Acid inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon]; Arachidonic Acid inhibits the reaction [PON1 protein results in increased hydrolysis of phenylacetic acid] Arachidonic Acid results in decreased activity of PON1 protein
Arachidonic Acid results in increased expression of PPARA mRNA; Arachidonic Acid results in increased expression of PPARA protein Arachidonic Acid binds to and results in increased activity of PPARA protein
Arachidonic Acid results in decreased expression of PPARG mRNA; Arachidonic Acid results in decreased expression of PPARG protein Arachidonic Acid results in increased expression of PPARG protein Arachidonic Acid promotes the reaction [Tetrachlorodibenzodioxin results in decreased expression of PPARG mRNA]
[Docosahexaenoic Acids co-treated with Arachidonic Acid] affects the expression of PTAFR mRNA; Arachidonic Acid inhibits the reaction [1-O-hexadecyl-2-N-methylcarbamylphosphatidylcholine results in increased expression of PTAFR mRNA]
Arachidonic Acid results in increased activity of PTGS1 protein PTGS1 results in increased susceptibility to Arachidonic Acid PTGS1 protein alternative form results in increased metabolism of Arachidonic Acid; PTGS1 protein results in increased metabolism of Arachidonic Acid [[Arachidonic Acid results in increased activity of PTGS1 protein] which results in increased susceptibility to 3,4-Methylenedioxyamphetamine] which results in increased abundance of 8-Hydroxy-2'-Deoxyguanosine; [[Arachidonic Acid results in increased activity of PTGS1 protein] which results in increased susceptibility to Methamphetamine] which results in increased abundance of 8-Hydroxy-2'-Deoxyguanosine; [Arachidonic Acid results in increased activity of PTGS1 protein] which results in increased susceptibility to 3,4-Methylenedioxyamphetamine; [Arachidonic Acid results in increased activity of PTGS1 protein] which results in increased susceptibility to Methamphetamine; [PTGS1 protein results in increased metabolism of Arachidonic Acid] which results in increased chemical synthesis of 12-hydroxy-5,8,10-heptadecatrienoic acid; [PTGS1 protein results in increased metabolism of Arachidonic Acid] which results in increased chemical synthesis of Thromboxane B2; arzanol inhibits the reaction [[PTGS1 protein results in increased metabolism of Arachidonic Acid] which results in increased chemical synthesis of 12-hydroxy-5,8,10-heptadecatrienoic acid]; arzanol inhibits the reaction [[PTGS1 protein results in increased metabolism of Arachidonic Acid] which results in increased chemical synthesis of Thromboxane B2]; Aspirin inhibits the reaction [[Arachidonic Acid results in increased activity of PTGS1 protein] which results in increased susceptibility to Methamphetamine]; Aspirin inhibits the reaction [Arachidonic Acid results in increased activity of PTGS1 protein]; DuP 697 inhibits the reaction [Arachidonic Acid results in increased activity of PTGS1 protein]; Resveratrol inhibits the reaction [Arachidonic Acid results in increased activity of PTGS1 protein]; SC 560 inhibits the reaction [Arachidonic Acid results in increased activity of PTGS1 protein]; valerylsalicylate inhibits the reaction [Arachidonic Acid results in increased activity of PTGS1 protein]
[[Arachidonic Acid results in increased activity of PTGS2 protein] which results in increased susceptibility to 3,4-Methylenedioxyamphetamine] which results in increased abundance of 8-Hydroxy-2'-Deoxyguanosine; [[Arachidonic Acid results in increased activity of PTGS2 protein] which results in increased susceptibility to Methamphetamine] which results in increased abundance of 8-Hydroxy-2'-Deoxyguanosine; [Arachidonic Acid results in increased abundance of Dinoprostone] promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]; [Arachidonic Acid results in increased activity of PTGS2 protein] which results in increased susceptibility to 3,4-Methylenedioxyamphetamine; [Arachidonic Acid results in increased activity of PTGS2 protein] which results in increased susceptibility to Methamphetamine; [lenabasum results in increased expression of PTGS2 mRNA] which results in increased secretion of Arachidonic Acid; [PTGS2 co-treated with Arachidonic Acid] results in increased expression of VEGFA; Arachidonic Acid inhibits the reaction [5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone binds to and results in decreased activity of PTGS2 protein]; Arachidonic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; Aspirin inhibits the reaction [[Arachidonic Acid results in increased activity of PTGS2 protein] which results in increased susceptibility to Methamphetamine]; Aspirin inhibits the reaction [Arachidonic Acid results in increased activity of PTGS2 protein]; Dinoprostone promotes the reaction [Arachidonic Acid results in increased expression of PTGS2 mRNA]; Flurbiprofen inhibits the reaction [Arachidonic Acid results in increased expression of PTGS2 mRNA]; Ibuprofen inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid]; nimesulide inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid] Arachidonic Acid results in increased expression of PTGS2 protein PTGS2 results in increased susceptibility to Arachidonic Acid 12-HPETE inhibits the reaction [Sodium Salicylate inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid]]; 2-methoxybenzoic acid inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid]; [Lipopolysaccharides results in increased expression of and results in increased activity of PTGS2 protein] which results in increased metabolism of Arachidonic Acid; [nimesulide results in decreased expression of PTGS2] which results in increased abundance of Arachidonic Acid; [PTGS2 protein results in increased abundance of prostaglandin G2] inhibits the reaction [Sodium Salicylate inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid]]; Arachidonic Acid affects the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA]; Benzoic Acid inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid]; Eugenol inhibits the reaction [[Lipopolysaccharides results in increased expression of and results in increased activity of PTGS2 protein] which results in increased metabolism of Arachidonic Acid]; Sodium Salicylate inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid] Arachidonic Acid results in increased expression of PTGS2 mRNA; Arachidonic Acid results in increased expression of PTGS2 protein
Arachidonic Acid results in increased expression of SELP protein Aspirin inhibits the reaction [Arachidonic Acid results in increased expression of SELP protein]; Glucose inhibits the reaction [Aspirin inhibits the reaction [Arachidonic Acid results in increased expression of SELP protein]]; Quercetin inhibits the reaction [Arachidonic Acid results in increased expression of SELP protein]
Arachidonic Acid results in decreased activity of SOD1 protein Arachidonic Acid results in increased activity of SOD1 protein 2,3,5-trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone inhibits the reaction [Arachidonic Acid results in decreased activity of SOD1 protein]; Indomethacin inhibits the reaction [Arachidonic Acid results in decreased activity of SOD1 protein]
[Arachidonic Acid results in increased abundance of Reactive Oxygen Species] which results in increased expression of SOD2; Acetylcysteine inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; Acetylcysteine inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 protein]; Arachidonic Acid results in increased expression of and results in increased activity of SOD2 protein; calphostin C inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; calphostin C inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 protein]; Dactinomycin inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; Indomethacin inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; Indomethacin inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 protein]; Masoprocol inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; Masoprocol inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 protein]; Phenols inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 protein] Arachidonic Acid results in increased activity of SOD2 protein 2,3,5-trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone inhibits the reaction [Arachidonic Acid results in increased activity of SOD2 protein]; Indomethacin inhibits the reaction [Arachidonic Acid results in increased activity of SOD2 protein]
Arachidonic Acid results in increased expression of STAR protein Arachidonic Acid inhibits the reaction [Dimethoate results in decreased expression of STAR protein]
[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TGFB1 mRNA; CYGB protein inhibits the reaction [[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TGFB1 mRNA]
Arachidonic Acid results in decreased expression of THRSP mRNA Flurbiprofen inhibits the reaction [Arachidonic Acid results in decreased expression of THRSP mRNA]
[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TIMP1 mRNA; CYGB protein inhibits the reaction [[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TIMP1 mRNA]
[Docosahexaenoic Acids co-treated with Arachidonic Acid] affects the expression of TLR4 mRNA; Arachidonic Acid inhibits the reaction [1-O-hexadecyl-2-N-methylcarbamylphosphatidylcholine results in increased expression of TLR4 mRNA]
Arachidonic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Butylated Hydroxyanisole inhibits the reaction [TNF protein results in increased secretion of Arachidonic Acid] TNF protein results in increased abundance of Arachidonic Acid Butylated Hydroxyanisole inhibits the reaction [TNF protein results in increased abundance of Arachidonic Acid]; TNFRSF1A protein affects the reaction [Butylated Hydroxyanisole inhibits the reaction [TNF protein results in increased abundance of Arachidonic Acid]]
TNFRSF1A protein affects the reaction [Butylated Hydroxyanisole inhibits the reaction [TNF protein results in increased abundance of Arachidonic Acid]]
[TP53 protein mutant form results in increased susceptibility to Niclosamide] which results in increased abundance of Arachidonic Acid [TP53 protein results in increased expression of ALOX12B mRNA] which results in increased metabolism of Arachidonic Acid; [TP53 protein results in increased expression of ALOX5 mRNA] which results in increased metabolism of Arachidonic Acid
Arachidonic Acid results in increased activity of TRPA1 protein Ruthenium Red inhibits the reaction [Arachidonic Acid results in increased activity of TRPA1 protein]
[PTGS2 co-treated with Arachidonic Acid] results in increased expression of VEGFA [Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK1 protein; [Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK3 protein; CYP2C23 mRNA promotes the reaction [[Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK1 protein]; CYP2C23 mRNA promotes the reaction [[Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK3 protein] Arachidonic Acid results in increased expression of VEGFA mRNA
arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of AVP mRNA]
[Streptozocin co-treated with arachidonyl-2-chloroethylamide] results in increased expression of BCL2 protein arachidonyl-2-chloroethylamide results in increased expression of BCL2 protein
arachidonyl-2-chloroethylamide results in decreased expression of CARTPT mRNA [arachidonyl-2-chloroethylamide co-treated with Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of CARTPT mRNA
arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]
arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]
CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK3 protein] CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of ESRRG mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein]
ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA] arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to DAGLA promoter]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA protein]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA] arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA; arachidonyl-2-chloroethylamide results in increased expression of DAGLA protein
arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA] arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to DAGLB promoter]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA]
arachidonyl-2-chloroethylamide results in increased expression of ESRRG mRNA; arachidonyl-2-chloroethylamide results in increased expression of ESRRG protein ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA] arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to DAGLA promoter]; arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to DAGLB promoter]; arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to FGF21 promoter]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of ESRRG mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA protein]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased secretion of FGF21 protein]
arachidonyl-2-chloroethylamide results in increased expression of FGA mRNA GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGA mRNA]
arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA arachidonyl-2-chloroethylamide results in increased secretion of FGF21 protein arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to FGF21 promoter]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased secretion of FGF21 protein]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased secretion of FGF21 protein] ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA] arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA; arachidonyl-2-chloroethylamide results in increased expression of FGF21 protein
arachidonyl-2-chloroethylamide results in increased expression of FGG mRNA GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGG mRNA]
FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of NFE2L2 mRNA]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of NRF1 mRNA]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of PPARGC1A mRNA]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of TFAM mRNA] arachidonyl-2-chloroethylamide results in decreased phosphorylation of FOXO1 protein
arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]
arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]
[arachidonyl-2-chloroethylamide co-treated with Glucose] results in increased secretion of INS1 protein; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein results in increased activity of GSR protein]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]
AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of MAPK1 protein]; arachidonyl-2-chloroethylamide promotes the reaction [Streptozocin results in increased phosphorylation of MAPK1 protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of MAPK1 protein] arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK1 protein arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]
AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of MAPK3 protein]; arachidonyl-2-chloroethylamide promotes the reaction [Streptozocin results in increased phosphorylation of MAPK3 protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of MAPK3 protein] arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]
Acetylcysteine inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of MPO protein]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of MPO protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of MPO protein]; SB 203580 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of MPO protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 protein]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 protein]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 protein]
arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of OXT mRNA]; arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased secretion of OXT protein]
arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]
arachidonyl-2-chloroethylamide promotes the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of PMCH mRNA] arachidonyl-2-chloroethylamide results in increased expression of PMCH mRNA
arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of POMC mRNA] arachidonyl-2-chloroethylamide results in decreased expression of POMC mRNA
AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide affects the localization of RELA protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide affects the localization of RELA protein]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide affects the localization of RELA protein]
AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of RHOA protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of RHOA protein]
arachidonyl-2-chloroethylamide results in decreased expression of TFAM mRNA FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of TFAM mRNA]
arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA; arachidonyl-2-chloroethylamide results in increased expression of TNF protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein]
AM 251 inhibits the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of VEGFA protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of VEGFA protein]
AM 251 inhibits the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of VEGFC protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of VEGFC protein]
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl arachidonate LIPG gene mutant form results in decreased abundance of cholesteryl arachidonate
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl linoleate LIPG gene mutant form affects the abundance of cholesteryl linoleate
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl linolenate LIPG gene mutant form results in increased abundance of cholesteryl linolenate
Linoleic Acids, Conjugated results in increased expression of ADGRE1 mRNA; Linoleic Acids, Conjugated results in increased expression of ADGRE1 protein
[picolinic acid co-treated with Linoleic Acids, Conjugated] results in increased expression of ADIPOQ protein Linoleic Acids, Conjugated results in decreased expression of ADIPOQ protein
Linoleic Acids, Conjugated results in decreased expression of ADIPOR2 mRNA rosiglitazone inhibits the reaction [Linoleic Acids, Conjugated results in decreased expression of ADIPOR2 mRNA]
Linoleic Acids, Conjugated results in decreased expression of CD36 mRNA rosiglitazone inhibits the reaction [Linoleic Acids, Conjugated results in decreased expression of CD36 mRNA]
Linoleic Acids, Conjugated results in decreased phosphorylation of and results in decreased activity of ESR1 protein; Okadaic Acid inhibits the reaction [Linoleic Acids, Conjugated results in decreased phosphorylation of ESR1 protein]
Linoleic Acids, Conjugated results in increased activity of GCLC protein [Linoleic Acids, Conjugated results in increased activity of GCLC protein] which results in decreased susceptibility to tert-Butylhydroperoxide Linoleic Acids, Conjugated results in increased expression of GCLC mRNA
Linoleic Acids, Conjugated results in increased activity of GSK3B protein Linoleic Acids, Conjugated results in decreased phosphorylation of GSK3B protein
Linoleic Acids, Conjugated results in increased expression of IL1B mRNA resveratrol inhibits the reaction [Linoleic Acids, Conjugated results in increased expression of IL1B mRNA]
Linoleic Acids, Conjugated results in increased expression of IL6 mRNA; Linoleic Acids, Conjugated results in increased expression of IL6 protein Linoleic Acids, Conjugated results in decreased expression of IL6 protein [Chromium co-treated with Linoleic Acids, Conjugated] results in decreased expression of IL6 protein resveratrol inhibits the reaction [Linoleic Acids, Conjugated results in increased expression of IL6 mRNA]
[Linoleic Acids, Conjugated co-treated with Chromium] results in decreased expression of INS1 protein Linoleic Acids, Conjugated results in decreased expression of INS1 protein
Linoleic Acids, Conjugated results in decreased expression of INS protein Linoleic Acids, Conjugated results in increased susceptibility to INS protein
[Linoleic Acids, Conjugated co-treated with Chromium] results in decreased expression of LEP protein Linoleic Acids, Conjugated results in decreased expression of LEP protein Linoleic Acids, Conjugated results in increased expression of LEP protein
rosiglitazone inhibits the reaction [Linoleic Acids, Conjugated results in decreased expression of LPL mRNA] Linoleic Acids, Conjugated results in increased activity of LPL protein
Linoleic Acids, Conjugated inhibits the reaction [Acrolein results in decreased activity of OGDH protein] Linoleic Acids, Conjugated results in increased activity of OGDH protein
Linoleic Acids, Conjugated results in decreased activity of PPARG protein Linoleic Acids, Conjugated results in increased expression of PPARG mRNA Linoleic Acids, Conjugated results in increased expression of PPARG mRNA; Linoleic Acids, Conjugated results in increased expression of PPARG protein Linoleic Acids, Conjugated results in increased phosphorylation of and results in increased activity of PPARG protein; resveratrol inhibits the reaction [Linoleic Acids, Conjugated results in decreased activity of PPARG protein]; resveratrol inhibits the reaction [Linoleic Acids, Conjugated results in increased phosphorylation of and results in increased activity of PPARG protein] Linoleic Acids, Conjugated results in decreased expression of PPARG protein
Linoleic Acids, Conjugated results in increased expression of PTGS2 mRNA; Linoleic Acids, Conjugated results in increased expression of PTGS2 protein [Linoleic Acids, Conjugated results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprost; Resveratrol inhibits the reaction [[Linoleic Acids, Conjugated results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprost]; Resveratrol inhibits the reaction [Linoleic Acids, Conjugated results in increased expression of PTGS2 mRNA]
[bisphenol A co-treated with Resveratrol co-treated with Corn Oil] results in decreased expression of CAT protein Corn Oil results in decreased expression of CAT protein
Corn Oil results in decreased expression of CLDN1 mRNA [(5'-(4-amino-7,7-dimethyl-2-trifluoromethyl-7H-pyrimido(4,5-b)(1,4)oxazin-6-yl)-2',3'-dihydrospiro(cyclohexane-1,1'-inden)-4-yl)acetic acid co-treated with Corn Oil] results in decreased expression of CLDN1 mRNA
Corn Oil results in increased expression of CPT1A mRNA [bisphenol A co-treated with Resveratrol co-treated with Corn Oil] results in increased expression of CPT1A mRNA Corn Oil affects the expression of CPT1A mRNA
Corn Oil affects the expression of CROT mRNA [bisphenol A co-treated with Resveratrol co-treated with Corn Oil] results in increased expression of CROT mRNA
[(5'-(4-amino-7,7-dimethyl-2-trifluoromethyl-7H-pyrimido(4,5-b)(1,4)oxazin-6-yl)-2',3'-dihydrospiro(cyclohexane-1,1'-inden)-4-yl)acetic acid co-treated with Corn Oil] results in increased activity of GPT protein; [Corn Oil co-treated with (5'-(4-amino-7,7-dimethyl-2-trifluoromethyl-7H-pyrimido(4,5-b)(1,4)oxazin-6-yl)-2',3'-dihydrospiro(cyclohexane-1,1'-inden)-4-yl)acetic acid] results in increased activity of GPT protein; Dactinomycin inhibits the reaction [[Corn Oil co-treated with (5'-(4-amino-7,7-dimethyl-2-trifluoromethyl-7H-pyrimido(4,5-b)(1,4)oxazin-6-yl)-2',3'-dihydrospiro(cyclohexane-1,1'-inden)-4-yl)acetic acid] results in increased activity of GPT protein]; Orlistat inhibits the reaction [[Corn Oil co-treated with (5'-(4-amino-7,7-dimethyl-2-trifluoromethyl-7H-pyrimido(4,5-b)(1,4)oxazin-6-yl)-2',3'-dihydrospiro(cyclohexane-1,1'-inden)-4-yl)acetic acid] results in increased activity of GPT protein]
Corn Oil results in increased expression of IL4 mRNA Corn Oil results in increased secretion of IL4 protein Corn Oil results in decreased expression of IL4 mRNA
[(5'-(4-amino-7,7-dimethyl-2-trifluoromethyl-7H-pyrimido(4,5-b)(1,4)oxazin-6-yl)-2',3'-dihydrospiro(cyclohexane-1,1'-inden)-4-yl)acetic acid co-treated with Corn Oil] results in decreased expression of OCLN mRNA
Corn Oil results in decreased activity of SOD1 protein [Corn Oil co-treated with Iron, Dietary] results in decreased activity of SOD1 protein; [Corn Oil co-treated with Iron] results in decreased activity of SOD1 protein; Iron promotes the reaction [Corn Oil results in decreased activity of SOD1 protein]; Iron, Dietary promotes the reaction [Corn Oil results in decreased activity of SOD1 protein]
[(5'-(4-amino-7,7-dimethyl-2-trifluoromethyl-7H-pyrimido(4,5-b)(1,4)oxazin-6-yl)-2',3'-dihydrospiro(cyclohexane-1,1'-inden)-4-yl)acetic acid co-treated with Corn Oil] results in decreased expression of TJP1 mRNA
crocin inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 mRNA]; crocin inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein]
crocin inhibits the reaction [Blood Glucose results in increased expression of ATG5 protein]; crocin promotes the reaction [Quercetin inhibits the reaction [Blood Glucose results in increased expression of ATG5 protein]]; Quercetin promotes the reaction [crocin inhibits the reaction [Blood Glucose results in increased expression of ATG5 protein]]
crocin inhibits the reaction [Arsenic Trioxide results in increased expression of BAX mRNA]; crocin inhibits the reaction [Arsenic Trioxide results in increased expression of BAX protein]; crocin inhibits the reaction [Diazinon results in increased expression of BAX mRNA]; crocin inhibits the reaction [Diazinon results in increased expression of BAX protein]; crocin inhibits the reaction [Malathion results in increased expression of BAX protein] crocin results in increased expression of BAX mRNA crocin inhibits the reaction [Zearalenone results in increased expression of BAX protein]
[crocin co-treated with Paraquat] results in decreased expression of BCL2 mRNA; crocin inhibits the reaction [Zearalenone results in decreased expression of BCL2 protein] crocin inhibits the reaction [Arsenic Trioxide results in decreased expression of BCL2 mRNA]; crocin inhibits the reaction [Arsenic Trioxide results in decreased expression of BCL2 protein] crocin results in decreased expression of BCL2 mRNA
crocin inhibits the reaction [Blood Glucose results in increased expression of BECN1 protein]; crocin inhibits the reaction [Blood Glucose results in increased phosphorylation of BECN1 protein]; crocin promotes the reaction [Quercetin inhibits the reaction [Blood Glucose results in increased expression of BECN1 protein]]; Quercetin promotes the reaction [crocin inhibits the reaction [Blood Glucose results in increased expression of BECN1 protein]]
crocin affects the reaction [Ethanol results in increased expression of CASP3 mRNA]; crocin inhibits the reaction [Arsenic Trioxide results in increased expression of CASP3 mRNA]; crocin inhibits the reaction [Arsenic Trioxide results in increased expression of CASP3 protein]; crocin inhibits the reaction [Carbon Tetrachloride results in increased activity of CASP3 protein]; crocin inhibits the reaction [Diazinon results in increased activity of CASP3 protein]; crocin inhibits the reaction [Diazinon results in increased cleavage of CASP3 protein]; crocin inhibits the reaction [Diazinon results in increased expression of CASP3 protein modified form]; crocin inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; crocin inhibits the reaction [Ethanol results in increased activity of CASP3 protein]; crocin inhibits the reaction [Malathion results in increased cleavage of CASP3 protein]; crocin inhibits the reaction [Tartrazine results in increased expression of CASP3 protein] crocin results in increased activity of CASP3 protein crocin results in increased expression of CASP3 mRNA crocin inhibits the reaction [Paraquat results in increased expression of CASP3 mRNA] Acetylcysteine inhibits the reaction [crocin results in increased activity of CASP3 protein]; MIR34A mRNA inhibits the reaction [crocin results in increased activity of CASP3 protein]; MYCN protein inhibits the reaction [crocin results in increased cleavage of CASP3 protein]; PTPN4 protein affects the reaction [crocin results in increased activity of CASP3 protein]
crocin inhibits the reaction [Diazinon results in increased cleavage of CASP9 protein]; crocin inhibits the reaction [Malathion results in increased cleavage of CASP9 protein] crocin results in increased activity of CASP9 protein
crocin inhibits the reaction [Arsenic Trioxide results in decreased activity of CAT protein]; crocin inhibits the reaction [Carbon Tetrachloride results in decreased activity of CAT protein]; crocin inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein]; crocin inhibits the reaction [Streptozocin results in decreased activity of CAT protein]; crocin inhibits the reaction [Tartrazine results in decreased activity of CAT protein]; crocin inhibits the reaction [Tartrazine results in decreased expression of CAT protein] crocin results in increased expression of CAT protein crocin results in decreased activity of CAT protein crocin inhibits the reaction [Patulin results in increased activity of CAT protein]; crocin inhibits the reaction [Zearalenone results in increased activity of CAT protein] crocin results in increased activity of CAT protein
[geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Amino Acids]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Pantothenic Acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of phenylpyruvic acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Allantoin]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Amino Acids]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Carnitine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Citric Acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Creatine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Creatinine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of phenylacetylglycine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Succinic Acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Uric Acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Uridine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased secretion of IL1B protein]
crocin inhibits the reaction [Carbon Tetrachloride results in decreased expression of CYP2E1 mRNA]; crocin inhibits the reaction [Carbon Tetrachloride results in increased activity of CYP2E1 protein] crocin results in decreased activity of CYP2E1 protein
crocin inhibits the reaction [Carbon Tetrachloride results in increased activity of GPT protein]; crocin inhibits the reaction [Cisplatin results in increased activity of GPT protein]; crocin inhibits the reaction [Tartrazine results in increased activity of GPT protein] crocin inhibits the reaction [Zearalenone results in increased expression of GPT protein]
[geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased secretion of IL1B protein]; crocin inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]; crocin inhibits the reaction [Doxorubicin results in increased expression of IL1B protein]
crocin inhibits the reaction [Arsenic Trioxide results in increased expression of IL6 mRNA]; crocin inhibits the reaction [Arsenic Trioxide results in increased expression of IL6 protein]; crocin inhibits the reaction [Carbon Tetrachloride results in increased expression of IL6 mRNA]; crocin inhibits the reaction [Carbon Tetrachloride results in increased expression of IL6 protein]; crocin inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein]; crocin inhibits the reaction [Ethanol results in decreased expression of IL6 protein]; crocin inhibits the reaction [Streptozocin results in increased expression of IL6 protein] crocin results in decreased expression of IL6 mRNA
[Quercetin co-treated with crocin] inhibits the reaction [Blood Glucose results in increased lipidation of MAP1LC3B protein]; crocin inhibits the reaction [Blood Glucose results in increased lipidation of MAP1LC3B protein]; Quercetin promotes the reaction [crocin inhibits the reaction [Blood Glucose results in increased lipidation of MAP1LC3B protein]]
crocin inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK1 protein]; crocin inhibits the reaction [Diazinon results in decreased phosphorylation of MAPK1 protein] crocin results in decreased phosphorylation of MAPK1 protein
crocin inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; crocin inhibits the reaction [Diazinon results in decreased phosphorylation of MAPK3 protein] crocin results in decreased phosphorylation of MAPK3 protein crocin inhibits the reaction [[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of MAPK3 mRNA]
crocin results in increased expression of MIR29B1 mRNA Cisplatin inhibits the reaction [crocin results in increased expression of MIR29B1 mRNA]; crocin inhibits the reaction [Cisplatin results in decreased expression of MIR29B1 mRNA]
MIR34A mRNA inhibits the reaction [crocin results in increased activity of CASP3 protein]; MIR34A mRNA inhibits the reaction [crocin results in increased expression of PTPN4 protein]
Cisplatin inhibits the reaction [crocin results in increased expression of MIR9-1 mRNA]; crocin inhibits the reaction [Cisplatin results in decreased expression of MIR9-1 mRNA]
MYCN results in decreased susceptibility to crocin crocin results in decreased expression of and results in decreased stability of MYCN mRNA; MYCN protein inhibits the reaction [crocin results in increased cleavage of CASP3 protein]; MYCN protein inhibits the reaction [crocin results in increased cleavage of PARP1 protein] crocin results in decreased expression of MYCN protein
crocin inhibits the reaction [Cisplatin results in increased expression of MYD88 mRNA]; crocin inhibits the reaction [Cisplatin results in increased expression of MYD88 protein]
crocin inhibits the reaction [Arsenic Trioxide results in decreased expression of NFE2L2 protein]; crocin inhibits the reaction [Cisplatin results in decreased expression of NFE2L2 protein]
[crocin co-treated with pyrazolanthrone co-treated with TNFSF11 protein] results in decreased expression of OSTM1 mRNA; crocin inhibits the reaction [[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of OSTM1 mRNA]
crocin promotes the reaction [Quercetin inhibits the reaction [Blood Glucose results in increased phosphorylation of PRKAB1 protein]]; Quercetin promotes the reaction [crocin inhibits the reaction [Blood Glucose results in increased phosphorylation of PRKAB1 protein]]
MIR34A mRNA inhibits the reaction [crocin results in increased expression of PTPN4 protein]; PTPN4 protein affects the reaction [crocin results in increased activity of CASP3 protein]
crocin inhibits the reaction [Arsenic Trioxide results in increased expression of RELA protein]; crocin inhibits the reaction [Streptozocin results in increased expression of RELA protein]
crocin results in decreased expression of SMAD2 protein Cisplatin inhibits the reaction [crocin results in decreased expression of SMAD2 protein]; crocin inhibits the reaction [Cisplatin results in increased expression of SMAD2 protein]
crocin inhibits the reaction [Malathion results in increased expression of SNCA mRNA]; crocin inhibits the reaction [Malathion results in increased expression of SNCA protein]
crocin inhibits the reaction [Blood Glucose results in decreased expression of SQSTM1 protein]; crocin promotes the reaction [Quercetin inhibits the reaction [Blood Glucose results in decreased expression of SQSTM1 protein]]; Quercetin promotes the reaction [crocin inhibits the reaction [Blood Glucose results in decreased expression of SQSTM1 protein]]
crocin inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of TGFB1 protein]; crocin inhibits the reaction [Blood Glucose results in increased expression of TGFB1 protein]; crocin inhibits the reaction [Carbon Tetrachloride results in increased expression of TGFB1 mRNA]; crocin inhibits the reaction [Cisplatin results in increased expression of TGFB1 protein]; crocin inhibits the reaction [Streptozocin results in increased expression of TGFB1 protein]; crocin promotes the reaction [Quercetin inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of TGFB1 protein]]; crocin promotes the reaction [Quercetin inhibits the reaction [Blood Glucose results in increased expression of TGFB1 protein]]; Quercetin promotes the reaction [crocin inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of TGFB1 protein]]; Quercetin promotes the reaction [crocin inhibits the reaction [Blood Glucose results in increased expression of TGFB1 protein]]
crocin inhibits the reaction [Cisplatin results in increased expression of TLR4 mRNA]; crocin inhibits the reaction [Cisplatin results in increased expression of TLR4 protein]; crocin inhibits the reaction [Streptozocin results in increased expression of TLR4 protein]
crocin inhibits the reaction [Arsenic Trioxide results in increased expression of TNF mRNA]; crocin inhibits the reaction [Arsenic Trioxide results in increased expression of TNF protein]; crocin inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF mRNA]; crocin inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]; crocin inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]; crocin inhibits the reaction [Doxorubicin results in increased expression of TNF protein]; crocin inhibits the reaction [Ethanol results in decreased expression of TNF protein] crocin results in decreased expression of TNF mRNA
[crocin co-treated with pyrazolanthrone co-treated with TNFSF11 protein] results in decreased expression of OSTM1 mRNA; crocin inhibits the reaction [[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of AKT2 mRNA]; crocin inhibits the reaction [[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of MAPK3 mRNA]; crocin inhibits the reaction [[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of OSTM1 mRNA]; crocin inhibits the reaction [[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of TRAF6 mRNA]; crocin inhibits the reaction [[TNFSF11 protein co-treated with Pyruvaldehyde] results in decreased activity of GLO1 protein]; crocin promotes the reaction [pyrazolanthrone inhibits the reaction [TNFSF11 protein results in increased activity of ACP5 protein]]
crocin inhibits the reaction [Paraquat results in increased expression of TRP53 mRNA]; crocin inhibits the reaction [Zearalenone results in increased expression of TRP53 protein]
[Flurbiprofen results in decreased activity of AKR1C3 protein] which results in increased chemical synthesis of farnesoic acid; [tolfenamic acid results in decreased activity of AKR1C3 protein] which results in increased chemical synthesis of farnesoic acid
[gamma-Linolenic Acid co-treated with Iodine co-treated with Selenium] results in increased expression of and results in increased localization of CLDN5 protein; [gamma-Linolenic Acid co-treated with Iodine] results in increased expression of and results in increased localization of CLDN5 protein; [Selenium co-treated with gamma-Linolenic Acid] results in increased expression of and results in increased localization of CLDN5 protein; gamma-Linolenic Acid results in increased expression of and results in increased localization of CLDN5 protein
[gamma-Linolenic Acid co-treated with Iodine co-treated with Selenium] results in increased expression of and results in increased localization of OCLN protein; [gamma-Linolenic Acid co-treated with Iodine] results in increased expression of and results in increased localization of OCLN protein; [Selenium co-treated with gamma-Linolenic Acid] results in increased expression of and results in increased localization of OCLN protein; gamma-Linolenic Acid results in increased expression of and results in increased localization of OCLN protein
[gamma-Linolenic Acid co-treated with Iodine co-treated with Selenium] results in increased expression of and results in increased localization of TJP1 protein
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of ACTB mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of ACTB mRNA
Ionomycin results in decreased expression of ADM mRNA Ionomycin results in decreased expression of ADM mRNA; Ionomycin results in decreased expression of ADM protein [Ionomycin co-treated with Lipopolysaccharides] results in decreased expression of ADM protein
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of AHR mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of and affects the localization of AHR protein
[Calcium co-treated with Ionomycin] results in increased phosphorylation of AKT1 protein; [Ionomycin co-treated with EGF protein] results in increased phosphorylation of AKT1 protein; CAMKK2 protein affects the reaction [[Calcium co-treated with Ionomycin] results in increased phosphorylation of AKT1 protein]; PDK1 protein affects the reaction [[Calcium co-treated with Ionomycin] results in increased phosphorylation of AKT1 protein]; PX-866 inhibits the reaction [[Calcium co-treated with Ionomycin] results in increased phosphorylation of AKT1 protein]; STO 609 inhibits the reaction [[Calcium co-treated with Ionomycin] results in increased phosphorylation of AKT1 protein]; W 7 inhibits the reaction [[Calcium co-treated with Ionomycin] results in increased phosphorylation of AKT1 protein]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of ARPC2 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of ARPC2 mRNA]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of ATF4 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of ATF4 mRNA Ionomycin results in increased expression of ATF4 protein
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of BCL2A1 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of BCL2A1 mRNA; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of BCL2A1 mRNA]]; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of BCL2A1 mRNA]
Ionomycin inhibits the reaction [MAP2K1 protein results in increased expression of CALCA mRNA] Ionomycin results in increased expression of CALCA mRNA [Ionomycin co-treated with Lipopolysaccharides] results in increased expression of CALCA protein; Ionomycin promotes the reaction [Lipopolysaccharides results in increased expression of CALCA mRNA]; Verapamil inhibits the reaction [[Ionomycin co-treated with Lipopolysaccharides] results in increased expression of CALCA protein] Ionomycin results in increased expression of CALCA protein
CALR protein results in decreased susceptibility to Ionomycin Ionomycin affects the reaction [CALR protein affects the expression of ACAN mRNA]; Ionomycin affects the reaction [CALR protein affects the expression of BGLAP mRNA]; Ionomycin affects the reaction [CALR protein affects the expression of RUNX2 mRNA]; Ionomycin affects the reaction [CALR protein affects the expression of SOX9 mRNA]; Ionomycin affects the reaction [CALR protein affects the expression of SP7 mRNA]
[Ionomycin co-treated with CAMK2A protein] inhibits the reaction [DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK1 protein]]; Ionomycin promotes the reaction [CAMK2A protein binds to ACTN1 protein]; Ionomycin promotes the reaction [CAMK2A protein binds to CDK5R1 protein]; Ionomycin promotes the reaction [CAMK2A protein binds to DRD3 protein]; Ionomycin promotes the reaction [CAMK2A protein binds to GRIN2B protein]; Ionomycin promotes the reaction [CAMK2A protein modified form binds to DRD3 protein]; KN 93 inhibits the reaction [Ionomycin promotes the reaction [CAMK2A protein binds to DRD3 protein]]; KN 93 inhibits the reaction [Ionomycin promotes the reaction [CAMK2A protein modified form binds to DRD3 protein]]
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of CASP3 protein; Calcium deficiency inhibits the reaction [Ionomycin results in increased activity of CASP3 protein]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CASP8 mRNA]; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of CASP8 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CASP8 mRNA; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CASP8 mRNA]]; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CASP8 mRNA]
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CCL11 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCL11 protein; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CCL11 protein]
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CCL2 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCL2 protein; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CCL2 protein]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCL3 mRNA]; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CCL3 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCL3 mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCL3 protein; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCL3 mRNA]
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CCL4 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCL4 protein; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CCL4 protein]
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CCL5 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCL5 protein; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CCL5 protein]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CCNG1 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CCNG1 mRNA]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCT5 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCT5 mRNA; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCT5 mRNA]]; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCT5 mRNA]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD200 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD200 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD200 mRNA]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD40LG mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD40LG protein
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD44 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD44 mRNA
Ionomycin results in increased expression of CD69 mRNA [Trichloroacetic Acid co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD69 protein 2-tert-butylhydroquinone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD69 protein]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD69 protein
[diethyl maleate co-treated with IL4 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD80 protein; [hexyl cinnamic aldehyde co-treated with IL4 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD80 protein
Ionomycin results in decreased expression of CD86 protein [diethyl maleate co-treated with IL4 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein; [hexyl cinnamic aldehyde co-treated with IL4 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein; [IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein; PRKCB protein affects the reaction [[IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CDH17 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CDH17 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CDH17 mRNA]
Egtazic Acid inhibits the reaction [Ionomycin results in decreased phosphorylation of and results in increased activity of CFL1 protein]; Ionomycin results in decreased phosphorylation of and results in increased activity of CFL1 protein
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of CHUK protein; Auranofin inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of CHUK protein]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CLN3 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CLN3 mRNA]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of COL6A1 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of COL6A1 mRNA]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of COMT mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of COMT mRNA
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CREM mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CREM mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CREM mRNA]
[IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Ionomycin] results in decreased expression of MIR146A mRNA; [IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein; [IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of MIR27A mRNA; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CSF2 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CSF2 protein; PRKCB protein affects the reaction [[IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein]; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CSF2 protein]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CTBP1 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CTBP1 mRNA]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CUL5 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CUL5 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CUL5 mRNA]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CYP1A1 mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CYP1A1 protein
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of DNAJC3 mRNA; deoxynivalenol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of DNAJC3 mRNA]
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of and results in increased activity of DNMT1 protein; Okadaic Acid promotes the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of and results in increased activity of DNMT1 protein]; PPP2CA protein affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of and results in increased activity of DNMT1 protein]; PPP2CB protein affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of and results in increased activity of DNMT1 protein]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [[FOS protein binds to JUN protein] which binds to DPYD promoter]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [[FOS protein binds to JUN protein] which results in increased expression of DPYD mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of DPYD mRNA
[Ionomycin co-treated with CAMK2A protein] inhibits the reaction [DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK1 protein]]; Ionomycin inhibits the reaction [[3,4,4a,10b-tetrahydro-4-propyl-2H,5H-(1)benzopyrano(4,3-b)-1,4-oxazin-9-ol results in increased activity of DRD3 protein] which results in increased phosphorylation of MAPK1 protein]; Ionomycin promotes the reaction [CAMK2A protein binds to DRD3 protein]; Ionomycin promotes the reaction [CAMK2A protein modified form binds to DRD3 protein]; KN 93 inhibits the reaction [Ionomycin promotes the reaction [CAMK2A protein binds to DRD3 protein]]; KN 93 inhibits the reaction [Ionomycin promotes the reaction [CAMK2A protein modified form binds to DRD3 protein]]; KN 93 inhibits the reaction [Ionomycin results in increased phosphorylation of DRD3 protein]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of DUSP4 mRNA; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of DUSP4 mRNA]]; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of DUSP4 mRNA]
[Ionomycin co-treated with EGF protein] results in increased phosphorylation of AKT1 protein; [Ionomycin co-treated with EGF protein] results in increased phosphorylation of MAPK1 protein; [Ionomycin co-treated with EGF protein] results in increased phosphorylation of MAPK3 protein; Ionomycin promotes the reaction [EGF protein promotes the reaction [CSNK2A1 protein binds to SLC39A7 protein]]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of EGR2 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of EGR2 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of EGR2 mRNA]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin co-treated with Estradiol] results in decreased expression of FASLG mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin co-treated with Estradiol] results in decreased expression of FASLG protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin co-treated with Testosterone] results in increased expression of FASLG mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin co-treated with Testosterone] results in increased expression of FASLG protein; Tamoxifen inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin co-treated with Estradiol] results in decreased expression of FASLG mRNA]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [[FOS protein binds to JUN protein] which binds to DPYD promoter]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [[FOS protein binds to JUN protein] which results in increased expression of DPYD mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of FOS protein; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of FOS protein]]; Capsaicin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of FOS protein]; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of FOS protein] Ionomycin results in increased expression of FOS mRNA 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid inhibits the reaction [Ionomycin results in increased expression of FOS mRNA]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of FOSL2 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of FOSL2 mRNA]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of FYB1 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of FYB1 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of FYB1 mRNA]
[PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of GATA3 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of GATA3 mRNA
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of GFRA2 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of GFRA2 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of GFRA2 mRNA]
2-tert-butylhydroquinone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of GZMB protein]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of GZMB protein
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HADHA mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HADHA mRNA
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of HARS1 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of HARS1 mRNA]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HCK mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HCK mRNA
Ionomycin results in increased secretion of HEXB protein Cyclosporine inhibits the reaction [Ionomycin results in increased secretion of HEXB protein]; KN 93 inhibits the reaction [Ionomycin results in increased secretion of HEXB protein]; ML 7 inhibits the reaction [Ionomycin results in increased secretion of HEXB protein]; N-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide inhibits the reaction [Ionomycin results in increased secretion of HEXB protein]
Curcumin analog inhibits the reaction [Ionomycin promotes the reaction [Oxygen deficiency results in increased activity of HIF1A protein]]; Curcumin analog inhibits the reaction [Ionomycin results in increased activity of HIF1A protein]; Ionomycin promotes the reaction [Oxygen deficiency results in increased activity of HIF1A protein]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of HMGB1 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of HMGB1 mRNA]
HRH2 protein affects the reaction [Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG protein]]; HRH2 protein affects the reaction [Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]]; HRH2 protein affects the reaction [Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 protein]]; HRH2 protein affects the reaction [Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF protein]]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HSPA5 mRNA; deoxynivalenol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HSPA5 mRNA]; deoxynivalenol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HSPA5 protein]
bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HSPA8 mRNA]]; pyrrolidine dithiocarbamic acid promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HSPA8 mRNA]
2-tert-butylhydroquinone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG protein]; 6-methoxyflavone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA]; [Benzocaine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG protein; [Cyclosporine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG protein; [Mercuric Chloride co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG protein; [Pentamidine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG protein; [PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA]; [tetrachloroplatinate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of and results in increased secretion of IFNG protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG protein; [Thalidomide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG protein; Dimaprit inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG protein]; Estradiol affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of and results in increased secretion of IFNG protein]; Famotidine inhibits the reaction [Dimaprit inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG protein]]; Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA]; Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG protein]; HRH2 protein affects the reaction [Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG protein]]; lactacystin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA]; Resveratrol affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of and results in increased secretion of IFNG protein]; tamibarotene inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG protein] 2-hydroxy-4-(2,2,3,3,3-pentafluoropropoxy)benzoic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA]; [2,4-diaminotoluene co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [2-anthramine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [4-nitroaniline co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Acetaminophen co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [Aluminum Chloride co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Amphotericin B co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Azathioprine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [Benzethonium co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Chloroquine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Chlorpromazine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Cisplatin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [citral co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [cobaltous chloride co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Colchicine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [Cyclophosphamide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [Cyclosporine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Dactinomycin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Dapsone co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [dibenzo(a,i)pyrene co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Dibutyl Phthalate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Dichloroacetic Acid co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA; [Digoxin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Dimethyl Sulfoxide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [FR 167653 co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Histamine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [Hydrocortisone co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [Hydrogen Peroxide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of IFNG promoter; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IFNG protein; [lead acetate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Lithium Carbonate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [Mercuric Chloride co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [Methotrexate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [Minocycline co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Mycophenolic Acid co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [Niacinamide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [nickel sulfate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Nitrofurazone co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [Pentamidine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Ribavirin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; [Sulfasalazine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Tacrolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IFNG protein; [Trichloroacetic Acid co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA; [Trichloroethylene co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA; [triethanolamine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Vehicle Emissions co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; Amiodarone inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG protein]; Aspirin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IFNG protein]; Cyclosporine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA]; nickel chloride inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of IFNG promoter]; Resveratrol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG protein]; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IFNG protein]; Zinc deficiency affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA] [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; benzamide inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA]; phenanthridone inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNGR2 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNGR2 mRNA]
4'-hydroxydiclofenac affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL10 protein]; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL10 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 protein; Acetaminophen affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL10 protein]; bisphenol A affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL10 protein]; catechol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 protein]; Hydrocortisone affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL10 protein]; hydroquinone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 protein]; hydroxyhydroquinone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 protein]; quinone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 protein]; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL10 protein] [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 mRNA 6-methoxyflavone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 mRNA]; 6-methoxyflavone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 protein]; [Benzocaine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL10 protein; [Cyclosporine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL10 protein; [Pentamidine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL10 protein; [PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 mRNA]; [Silicon Dioxide co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased secretion of IL10 protein; [Sirolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL10 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of and results in increased secretion of IL10 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 protein; Genistein affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of and results in increased secretion of IL10 protein]
6-methoxyflavone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL13 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL13 mRNA; lactacystin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL13 mRNA]
1,1,1,3,3,3-hexafluoro-2-(2-fluoro-4'-((4-(pyridin-4-ylmethyl)piperazin-1-yl)methyl)-(1,1'-biphenyl)-4-yl)propan-2-ol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA]; 1,1,1,3,3,3-hexafluoro-2-(2-fluoro-4'-((4-(pyridin-4-ylmethyl)piperazin-1-yl)methyl)-(1,1'-biphenyl)-4-yl)propan-2-ol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A protein]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of and results in increased secretion of IL17A protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A protein; biochanin A promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA]; daidzein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA]; Digoxin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA]; Digoxin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A protein]; enilconazole inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA]; formononetin promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA]; Genistein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA]; hexaconazole inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA]; T0901317 inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA]; tetraconazole inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA]; triflumizol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA]; yakuchinone-A inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of and results in increased secretion of IL17A protein] [Trinitrobenzenesulfonic Acid results in increased susceptibility to [Ionomycin co-treated with Tetradecanoylphorbol Acetate]] which results in increased expression of IL17A protein
[Ionomycin co-treated with IL1A protein] results in decreased secretion of IL4 protein; [Ionomycin co-treated with IL1A protein] results in increased secretion of IL6 protein; [Ionomycin co-treated with IL1A protein] results in increased secretion of IL9 protein; [Ionomycin co-treated with IL1A protein] results in increased secretion of TNF protein; IL1A protein promotes the reaction [Ionomycin results in increased expression of IL9 mRNA]; IL1RN protein inhibits the reaction [[Ionomycin co-treated with IL1A protein] results in increased secretion of IL9 protein]; IL4 protein affects the reaction [[Ionomycin co-treated with IL1A protein] results in increased secretion of IL3 protein]; IL4 protein affects the reaction [[Ionomycin co-treated with IL1A protein] results in increased secretion of IL6 protein]; IL4 protein affects the reaction [[Ionomycin co-treated with IL1A protein] results in increased secretion of IL9 protein]
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL1B protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL1B protein; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL1B protein]
[Benzocaine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 protein; [bis(tri-n-butyltin)oxide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 protein; [Cyclosporine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein; [Pentamidine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 protein; [Sirolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 protein; [Sodium Dodecyl Sulfate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 protein; [tetrachloroplatinate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin co-treated with IL2 protein] results in increased expression of IL2RA protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IL2 protein; [Thalidomide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 protein; anethole inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA]; anethole inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IL2 protein]; Cannabinol inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA]; Cannabinol inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]; deoxynivalenol promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA]; deoxynivalenol promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]; di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin co-treated with IL2 protein] results in increased expression of IL2RA protein]; Dimaprit inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]; Dronabinol inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA]; Dronabinol inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]; Famotidine inhibits the reaction [Dimaprit inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]]; Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]; HRH2 protein affects the reaction [Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]]; isoeugenol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA]; isoeugenol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IL2 protein]; lactacystin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA]; PLD2 protein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein] 1-Butanol inhibits the reaction [[4-O-methyl-12-O-tetradecanoylphorbol 13-acetate co-treated with Ionomycin] results in increased expression of IL2 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [norcantharidin inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]]; 4'-hydroxydiclofenac affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]; [2-anthramine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [4-nitroaniline co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Acetaminophen co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; [Aluminum Chloride co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Amphotericin B co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Benzethonium co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Chloroquine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Chlorpromazine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Cisplatin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [citral co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [cobaltous chloride co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Colchicine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; [Cyclosporine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Dactinomycin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Dapsone co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Dexamethasone co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [dibenzo(a,i)pyrene co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Dibutyl Phthalate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Dichloroacetic Acid co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA; [Dichloroacetic Acid co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein; [diethanolamine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Digoxin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Dimethyl Sulfoxide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; [Formaldehyde co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [FR 167653 co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Histamine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Hydrocortisone co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Hydrogen Peroxide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of IL2 promoter; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein; [Isoniazid co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [isophorone diisocyanate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [lead acetate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Lithium Carbonate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Methotrexate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; [Minocycline co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Mitomycin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Mycophenolic Acid co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; [Niacinamide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; [nickel sulfate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Nitrofurazone co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Pentamidine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Pyrimethamine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Ribavirin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; [Sirolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; [sodium bromate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Sulfasalazine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Tacrolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IL2 mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IL2 protein; [Trichloroacetic Acid co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA; [Trichloroacetic Acid co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein; [Trichloroethylene co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA; [Trichloroethylene co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein; [triethanolamine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Vehicle Emissions co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; [Warfarin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; Amiodarone inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 protein]; Aspirin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IL2 protein]; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA]]; bisphenol A affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]; Diclofenac affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]; Go 6976 inhibits the reaction [pomalidomide promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]]; Hydrocortisone affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]; Lenalidomide promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IL2 protein]; nickel chloride inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of IL2 promoter]; norcantharidin inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]; Peptides inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]; PLD2 protein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]; pomalidomide promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA]; pomalidomide promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]; pomalidomide promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IL2 protein]; Pyrazoles analog inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA]; Pyrazoles analog inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IL2 mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA]; Quercetin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA]; Resveratrol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]; rottlerin inhibits the reaction [pomalidomide promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]]; SB 203580 inhibits the reaction [norcantharidin inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]]; Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of IL2 protein]; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]; tert-Butyl Alcohol inhibits the reaction [[4-O-methyl-12-O-tetradecanoylphorbol 13-acetate co-treated with Ionomycin] results in increased expression of IL2 protein]; U 0126 inhibits the reaction [[4-O-methyl-12-O-tetradecanoylphorbol 13-acetate co-treated with Ionomycin] results in increased expression of IL2 protein]; Zinc deficiency affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA]; Zinc Sulfate inhibits the reaction [Ionomycin results in increased expression of IL2 mRNA] [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; benzamide inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA]; phenanthridone inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA]
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL21 protein; tamibarotene inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL21 protein]
1,1,1,3,3,3-hexafluoro-2-(2-fluoro-4'-((4-(pyridin-4-ylmethyl)piperazin-1-yl)methyl)-(1,1'-biphenyl)-4-yl)propan-2-ol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL23R mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL23R mRNA; Digoxin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL23R mRNA]
[Dichloroacetic Acid co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2RA protein; [Trichloroacetic Acid co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA protein; [Trichloroethylene co-treated with Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA protein; Cyclosporine inhibits the reaction [Ionomycin results in increased secretion of IL2RA protein]; Sirolimus inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2RA protein]; Sirolimus inhibits the reaction [Ionomycin results in increased secretion of IL2RA protein] 2-tert-butylhydroquinone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA protein]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin co-treated with IL2 protein] results in increased expression of IL2RA protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA protein; Acetylcysteine inhibits the reaction [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA protein]]; bathocuproine sulfonate inhibits the reaction [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA protein]]; di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin co-treated with IL2 protein] results in increased expression of IL2RA protein]; di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA mRNA]; di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA protein]; lactacystin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA mRNA]; tetrathiomolybdate inhibits the reaction [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA protein]] [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2RA protein
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RB mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RB mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RB mRNA]
4'-hydroxydiclofenac affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL4 protein]; [diethyl maleate co-treated with IL4 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD80 protein; [diethyl maleate co-treated with IL4 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein; [hexyl cinnamic aldehyde co-treated with IL4 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD80 protein; [hexyl cinnamic aldehyde co-treated with IL4 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein; [IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Ionomycin] results in decreased expression of MIR146A mRNA; [IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein; [IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of MIR27A mRNA; [Ionomycin co-treated with IL1A protein] results in decreased secretion of IL4 protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL4 protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL4 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 protein; Amiodarone inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL4 protein]; IL4 protein affects the reaction [[Ionomycin co-treated with IL1A protein] results in increased secretion of IL3 protein]; IL4 protein affects the reaction [[Ionomycin co-treated with IL1A protein] results in increased secretion of IL6 protein]; IL4 protein affects the reaction [[Ionomycin co-treated with IL1A protein] results in increased secretion of IL9 protein]; PRKCB protein affects the reaction [[IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein]; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL4 protein] [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 mRNA; Cyclosporine inhibits the reaction [IL4 protein promotes the reaction [Ionomycin results in increased expression of TNFRSF4 protein]]; IL4 protein promotes the reaction [Ionomycin results in increased expression of TNFRSF4 protein]; Staurosporine inhibits the reaction [IL4 protein promotes the reaction [Ionomycin results in increased expression of TNFRSF4 protein]] 6-methoxyflavone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [NFATC2 protein binds to IL4 promoter]]; 6-methoxyflavone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 mRNA]; 6-methoxyflavone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 protein]; [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [NFATC3 protein binds to IL4 promoter]] which results in increased expression of IL4 mRNA; [Cyclosporine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL4 protein; [Pentamidine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL4 protein; [PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 mRNA]; [Sirolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL4 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [NFATC2 protein binds to IL4 promoter]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [NFATC3 protein binds to IL4 promoter]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 protein; [Toluene 2,4-Diisocyanate co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL4 protein; bisphenol A promotes the reaction [[[Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [NFATC3 protein binds to IL4 promoter]] which results in increased expression of IL4 mRNA]; deoxynivalenol promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 mRNA]; deoxynivalenol promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 protein]; Dimaprit inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 protein]; Famotidine inhibits the reaction [Dimaprit inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 protein]]; Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 protein]; HRH2 protein affects the reaction [Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 protein]]; lactacystin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 mRNA]; nonylphenol promotes the reaction [[[Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [NFATC3 protein binds to IL4 promoter]] which results in increased expression of IL4 mRNA]
2-hydroxy-4-(2,2,3,3,3-pentafluoropropoxy)benzoic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL5 mRNA]; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL5 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL5 mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL5 protein; Cyclosporine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL5 mRNA]; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL5 protein] deoxynivalenol promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL5 mRNA]; deoxynivalenol promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL5 protein]
4'-hydroxydiclofenac affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL6 protein]; [Ionomycin co-treated with IL1A protein] results in increased secretion of IL6 protein; [Ionomycin co-treated with Lipopolysaccharides] results in increased expression of IL6 protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL6 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL6 mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL6 protein; Acetaminophen affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL6 protein]; bisphenol A affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL6 protein]; Diclofenac affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL6 protein]; IL4 protein affects the reaction [[Ionomycin co-treated with IL1A protein] results in increased secretion of IL6 protein]; Ionomycin promotes the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL6 protein] Ionomycin results in increased expression of IL6 mRNA
Ionomycin results in increased expression of IL9 mRNA [Ionomycin co-treated with IL1A protein] results in increased secretion of IL9 protein; IL1A protein promotes the reaction [Ionomycin results in increased expression of IL9 mRNA]; IL1RN protein inhibits the reaction [[Ionomycin co-treated with IL1A protein] results in increased secretion of IL9 protein]; IL4 protein affects the reaction [[Ionomycin co-treated with IL1A protein] results in increased secretion of IL9 protein]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IRF4 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IRF4 mRNA]
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of JUN protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [[FOS protein binds to JUN protein] which binds to DPYD promoter]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [[FOS protein binds to JUN protein] which results in increased expression of DPYD mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN protein; Amiodarone inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of JUN protein]; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN protein]]; Capsaicin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN protein]; Methohexital inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN mRNA]; Pentobarbital inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN mRNA]; pyrrolidine dithiocarbamic acid promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN protein]; Secobarbital inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN mRNA]; Thiamylal inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN mRNA]; Thiopental inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN mRNA]
[Ionomycin results in increased activity of KCNN3 protein] which results in increased import of Thallium; Apamin inhibits the reaction [[Ionomycin results in increased activity of KCNN3 protein] which results in increased import of Thallium]
[Ionomycin co-treated with Tetraethylammonium] results in increased activity of KCNN4 protein; Clotrimazole inhibits the reaction [[Ionomycin co-treated with Tetraethylammonium] results in increased activity of KCNN4 protein]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of KLF4 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of KLF4 mRNA]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of KLF6 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of KLF6 mRNA]
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] promotes the reaction [NFATC2 protein binds to KPNB1 protein]; Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] promotes the reaction [NFATC2 protein binds to KPNB1 protein]]
Methohexital inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of KRAS protein]; Pentobarbital inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of KRAS protein]; Secobarbital inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of KRAS protein]; Thiamylal inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of KRAS protein]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of LCP1 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of LCP1 mRNA
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of LTBP4 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of LTBP4 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of LTBP4 mRNA]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of MAP2K2 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of MAP2K2 mRNA]
1-Butanol inhibits the reaction [[4-O-methyl-12-O-tetradecanoylphorbol 13-acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK1 protein]; [Ionomycin co-treated with EGF protein] results in increased phosphorylation of MAPK1 protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK1 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK1 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of MAPK1 protein; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of MAPK1 protein]]; Okadaic Acid promotes the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK1 protein]; PLD2 protein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK1 protein]; PPP2CA protein affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK1 protein]; PPP2CB protein affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK1 protein]; pyrrolidine dithiocarbamic acid promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of MAPK1 protein] [Ionomycin co-treated with CAMK2A protein] inhibits the reaction [DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK1 protein]]; Ionomycin inhibits the reaction [[3,4,4a,10b-tetrahydro-4-propyl-2H,5H-(1)benzopyrano(4,3-b)-1,4-oxazin-9-ol results in increased activity of DRD3 protein] which results in increased phosphorylation of MAPK1 protein]; Ionomycin results in increased phosphorylation of and results in increased activity of MAPK1 protein [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK1 protein; PLD2 protein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK1 protein]
[Ionomycin co-treated with EGF protein] results in increased phosphorylation of MAPK3 protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK3 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK3 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of MAPK3 protein; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of MAPK3 protein]]; Okadaic Acid promotes the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK3 protein]; PLD2 protein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK3 protein]; PPP2CA protein affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK3 protein]; PPP2CB protein affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK3 protein]; pyrrolidine dithiocarbamic acid promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [[4-O-methyl-12-O-tetradecanoylphorbol 13-acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK3 protein] Ionomycin results in increased phosphorylation of and results in increased activity of MAPK3 protein [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK3 protein; PLD2 protein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK3 protein]
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK8 protein; Amiodarone inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK8 protein]
Ionomycin results in decreased phosphorylation of MAPT protein Okadaic Acid inhibits the reaction [Ionomycin results in decreased phosphorylation of MAPT protein]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of MYC mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of MYC mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of MYC mRNA]
Ionomycin results in increased phosphorylation of MYL9 protein Trifluoperazine inhibits the reaction [Ionomycin results in increased phosphorylation of MYL9 protein]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of NAA80 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of NAA80 mRNA
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of NELL1 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of NELL1 mRNA
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] affects the localization of NFATC2 protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] promotes the reaction [NFATC2 protein binds to KPNB1 protein]; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of NFATC2 protein; Acetic Acid inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of NFATC2 protein]; Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] affects the localization of NFATC2 protein]; Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] promotes the reaction [NFATC2 protein binds to KPNB1 protein]]; Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of NFATC2 protein] 6-methoxyflavone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] affects the localization of NFATC2 protein]; 6-methoxyflavone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [NFATC2 protein binds to IL4 promoter]]; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] affects the localization of and results in decreased phosphorylation of NFATC2 protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [NFATC2 protein binds to IL4 promoter]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased phosphorylation of and affects the localization of NFATC2 protein; Cyclosporine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased phosphorylation of and affects the localization of NFATC2 protein]; Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] affects the localization of NFATC2 protein]
[[Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [NFATC3 protein binds to IL4 promoter]] which results in increased expression of IL4 mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [NFATC3 protein binds to IL4 promoter]; bisphenol A promotes the reaction [[[Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [NFATC3 protein binds to IL4 promoter]] which results in increased expression of IL4 mRNA]; nonylphenol promotes the reaction [[[Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [NFATC3 protein binds to IL4 promoter]] which results in increased expression of IL4 mRNA] Ionomycin affects the localization of NFATC3 protein
NFE2L2 gene mutant form results in increased susceptibility to Ionomycin [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of NFE2L2 protein NFE2L2 protein results in decreased susceptibility to Ionomycin
[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased degradation of NFKBIA protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased degradation of NFKBIA protein; Amiodarone inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased degradation of NFKBIA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased degradation of NFKBIA protein]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of NKG7 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of NKG7 mRNA]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of NMI mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of NMI mRNA
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of NOTCH3 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of NOTCH3 mRNA]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of NR4A3 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of NR4A3 mRNA
PLD2 protein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]; PLD2 protein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK1 protein]; PLD2 protein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK3 protein]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of PNPLA4 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of PNPLA4 mRNA]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of POU2F2 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of POU2F2 mRNA]
Cyclosporine inhibits the reaction [Ionomycin results in increased expression of PPARGC1A mRNA]; KN 62 affects the reaction [Ionomycin results in increased expression of PPARGC1A mRNA]
PPP2CA protein affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of and results in increased activity of DNMT1 protein]; PPP2CA protein affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK1 protein]; PPP2CA protein affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK3 protein]
PPP2CB protein affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of and results in increased activity of DNMT1 protein]; PPP2CB protein affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK1 protein]; PPP2CB protein affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of MAPK3 protein]
2-tert-butylhydroquinone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of PRF1 protein]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of PRF1 protein
PRKCB protein affects the reaction [[IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of PRKCQ protein; pomalidomide promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of PRKCQ protein]
[PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of GATA3 mRNA]; [PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA]; [PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 mRNA]; [PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 mRNA]; [PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TBX21 mRNA]; [PSMB8 protein co-treated with PSMB10 protein] affects the susceptibility to [Tetradecanoylphorbol Acetate co-treated with Ionomycin]
[PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of GATA3 mRNA]; [PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA]; [PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 mRNA]; [PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 mRNA]; [PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TBX21 mRNA]; [PSMB8 protein co-treated with PSMB10 protein] affects the susceptibility to [Tetradecanoylphorbol Acetate co-treated with Ionomycin]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of REL mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of REL mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of REL mRNA]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of RHOG mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of RHOG mRNA]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of RNASET2 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of RNASET2 mRNA]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of SART1 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of SART1 mRNA]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of SF3B4 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of SF3B4 mRNA]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of SLA mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of SLA mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of SLA mRNA]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of SLC3A2 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of SLC3A2 mRNA]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of SRPRA mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of SRPRA mRNA
[PSMB8 protein co-treated with PSMB10 protein] affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TBX21 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TBX21 mRNA; lactacystin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TBX21 mRNA]
4'-hydroxydiclofenac affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of TNF protein]; [diethyl maleate co-treated with IL4 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD80 protein; [diethyl maleate co-treated with IL4 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein; [hexyl cinnamic aldehyde co-treated with IL4 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD80 protein; [hexyl cinnamic aldehyde co-treated with IL4 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein; [IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Ionomycin] results in decreased expression of MIR146A mRNA; [IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein; [IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of MIR27A mRNA; [Ionomycin co-treated with IL1A protein] results in increased secretion of TNF protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of TNF protein; [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of TNF protein; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF protein; Amiodarone inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of TNF protein]; Diclofenac affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of TNF protein]; Hydrocortisone affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of TNF protein]; hydroquinone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF protein]; Ionomycin inhibits the reaction [[N-(4-hydroxyphenyl)arachidonylamide co-treated with Tetradecanoylphorbol Acetate] results in increased expression of TNF protein]; Peptides inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF protein]; PRKCB protein affects the reaction [[IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Ionomycin] results in increased expression of CD86 protein]; Resveratrol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF protein]; sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of TNF protein] [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of TNF mRNA; benzamide inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of TNF mRNA]; phenanthridone inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of TNF mRNA] [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF mRNA; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF protein; Dimaprit inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF protein]; Famotidine inhibits the reaction [Dimaprit inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF protein]]; Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF protein]; HRH2 protein affects the reaction [Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF protein]]; lactacystin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF mRNA]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of TNFRSF1B mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of TNFRSF1B mRNA
Cyclosporine inhibits the reaction [IL4 protein promotes the reaction [Ionomycin results in increased expression of TNFRSF4 protein]]; Cyclosporine inhibits the reaction [Ionomycin promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNFRSF4 protein]]; Cyclosporine inhibits the reaction [Ionomycin results in increased expression of TNFRSF4 protein]; IL4 protein promotes the reaction [Ionomycin results in increased expression of TNFRSF4 protein]; Ionomycin promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNFRSF4 protein]; Staurosporine inhibits the reaction [IL4 protein promotes the reaction [Ionomycin results in increased expression of TNFRSF4 protein]]; Staurosporine inhibits the reaction [Ionomycin promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNFRSF4 protein]]
[Ionomycin co-treated with Phorbol Esters] promotes the reaction [entinostat results in increased expression of TNFSF9 mRNA]; [Ionomycin co-treated with Phorbol Esters] promotes the reaction [trichostatin A results in increased expression of TNFSF9 mRNA]; [Ionomycin co-treated with Phorbol Esters] promotes the reaction [vorinostat results in increased expression of TNFSF9 mRNA]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TRAF1 mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TRAF1 mRNA; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TRAF1 mRNA]]; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TRAF1 mRNA]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of TRIB2 mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of TRIB2 mRNA]
[Ionomycin co-treated with Calcium co-treated with CAMK2D protein] results in increased activity of TRPM4 protein Ionomycin results in increased activity of TRPM4 protein
Ionomycin promotes the reaction [Calcium Chloride inhibits the reaction [resiniferatoxin affects the reaction [[Sodium Chloride co-treated with benzamil] results in increased activity of TRPV1 protein]]] Ionomycin results in increased activity of TRPV1 protein Ionomycin inhibits the reaction [Calcium Chloride results in increased activity of TRPV1 protein]; Ionomycin inhibits the reaction [resiniferatoxin affects the reaction [[Sodium Chloride co-treated with benzamil] results in increased activity of TRPV1 protein]]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of TYROBP mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of TYROBP mRNA; pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of TYROBP mRNA]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of VIM mRNA]; [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of VIM mRNA
leptomycin B inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; leptomycin B inhibits the reaction [Formaldehyde affects the phosphorylation of AKT1 protein]; leptomycin B inhibits the reaction [Gefitinib results in decreased phosphorylation of AKT1 protein] leptomycin B results in increased phosphorylation of AKT1 protein
leptomycin B affects the localization of BACH1 protein leptomycin B inhibits the reaction [Cannabidiol results in decreased expression of BACH1 protein] leptomycin B inhibits the reaction [Cadmium Chloride affects the localization of BACH1 protein]; leptomycin B inhibits the reaction [Cadmium results in decreased activity of BACH1 protein]
[epigallocatechin gallate co-treated with leptomycin B] results in decreased expression of BIRC5 mRNA; [epigallocatechin gallate co-treated with leptomycin B] results in decreased expression of BIRC5 protein; [leptomycin B co-treated with TP53 gene mutant form] results in increased expression of BIRC5 mRNA; leptomycin B promotes the reaction [gefitinib results in decreased expression of BIRC5 protein]; TP53 gene mutant form inhibits the reaction [leptomycin B results in decreased expression of BIRC5 protein] leptomycin B results in decreased expression of BIRC5 mRNA; leptomycin B results in decreased expression of BIRC5 protein
[leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of BRCA1 mRNA leptomycin B results in decreased expression of BRCA1 mRNA
leptomycin B results in increased secretion of CCL2 protein polydatin inhibits the reaction [leptomycin B results in increased secretion of CCL2 protein]
[epigallocatechin gallate co-treated with leptomycin B] results in increased expression of CDKN1A mRNA; [epigallocatechin gallate co-treated with leptomycin B] results in increased expression of CDKN1A protein; leptomycin B inhibits the reaction [gefitinib results in decreased expression of CDKN1A protein]; TP53 gene mutant form inhibits the reaction [leptomycin B results in increased expression of CDKN1A protein] leptomycin B results in increased expression of CDKN1A mRNA; leptomycin B results in increased expression of CDKN1A protein
leptomycin B results in decreased secretion of CXCL10 protein acteoside promotes the reaction [leptomycin B results in decreased secretion of CXCL10 protein]; Quercetin promotes the reaction [leptomycin B results in decreased secretion of CXCL10 protein]
leptomycin B results in increased expression of CYP3A4 mRNA [epigallocatechin gallate co-treated with leptomycin B] results in increased expression of CYP3A4 mRNA
[leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of DNMT1 mRNA leptomycin B results in decreased expression of DNMT1 mRNA
leptomycin B inhibits the reaction [EGF protein affects the localization of SET protein alternative form]; leptomycin B inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]
leptomycin B results in increased expression of GPX1 mRNA [epigallocatechin gallate co-treated with leptomycin B] results in increased expression of GPX1 mRNA
leptomycin B results in increased phosphorylation of MAPK1 protein leptomycin B inhibits the reaction [gefitinib results in decreased phosphorylation of MAPK1 protein]
leptomycin B inhibits the reaction [gefitinib results in decreased phosphorylation of MAPK3 protein] leptomycin B results in increased phosphorylation of MAPK3 protein
leptomycin B affects the localization of RANBP1 protein leptomycin B inhibits the reaction [Phenylephrine affects the localization of and affects the expression of RANBP1 protein]
leptomycin B affects the reaction [Formaldehyde affects the localization of SET protein alternative form]; leptomycin B inhibits the reaction [EGF protein affects the localization of SET protein alternative form]
leptomycin B inhibits the reaction [arsenite inhibits the reaction [TGFB2 protein affects the localization of SMAD2 protein]]; leptomycin B inhibits the reaction [arsenite inhibits the reaction [XPO4 protein results in increased export of SMAD2 protein]]; leptomycin B inhibits the reaction [monomethylarsonous acid inhibits the reaction [TGFB2 protein affects the localization of SMAD2 protein]]; leptomycin B inhibits the reaction [monomethylarsonous acid inhibits the reaction [XPO4 protein results in increased export of SMAD2 protein]]
leptomycin B inhibits the reaction [arsenite inhibits the reaction [TGFB2 protein affects the localization of SMAD3 protein]]; leptomycin B inhibits the reaction [arsenite inhibits the reaction [XPO4 protein results in increased export of SMAD3 protein]]; leptomycin B inhibits the reaction [monomethylarsonous acid inhibits the reaction [TGFB2 protein affects the localization of SMAD3 protein]]; leptomycin B inhibits the reaction [monomethylarsonous acid inhibits the reaction [XPO4 protein results in increased export of SMAD3 protein]]
leptomycin B results in increased expression of SOD2 mRNA [epigallocatechin gallate co-treated with leptomycin B] results in increased expression of SOD2 mRNA
leptomycin B inhibits the reaction [arsenite inhibits the reaction [TGFB2 protein affects the localization of SMAD2 protein]]; leptomycin B inhibits the reaction [arsenite inhibits the reaction [TGFB2 protein affects the localization of SMAD3 protein]]; leptomycin B inhibits the reaction [monomethylarsonous acid inhibits the reaction [TGFB2 protein affects the localization of SMAD2 protein]]; leptomycin B inhibits the reaction [monomethylarsonous acid inhibits the reaction [TGFB2 protein affects the localization of SMAD3 protein]]
3,4,5,3',4'-pentachlorobiphenyl inhibits the reaction [leptomycin B results in increased expression of TP53 protein]; [leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of BRCA1 mRNA; [leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of CHEK2 mRNA; [leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of DNMT1 mRNA; [leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of HK2 mRNA; [leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of MDM4 mRNA; [leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of PRKCA mRNA; [leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of TP63 mRNA; [leptomycin B co-treated with TP53 gene mutant form] results in increased expression of APAF1 mRNA; [leptomycin B co-treated with TP53 gene mutant form] results in increased expression of BIRC5 mRNA; [leptomycin B co-treated with TP53 gene mutant form] results in increased expression of IL6 mRNA; [leptomycin B co-treated with TP53 gene mutant form] results in increased expression of NFKB1 mRNA; [leptomycin B co-treated with TP53 gene mutant form] results in increased expression of TNFRSF10D mRNA; [sodium arsenite co-treated with leptomycin B] results in increased phosphorylation of TP53 protein; leptomycin B affects the localization of and results in decreased degradation of TP53 protein; leptomycin B inhibits the reaction [Cycloheximide results in increased degradation of TP53 protein]; leptomycin B inhibits the reaction [sodium arsenite affects the localization of TP53 protein]; leptomycin B inhibits the reaction [sodium arsenite results in increased degradation of TP53 protein mutant form]; leptomycin B inhibits the reaction [TP53 protein results in increased susceptibility to trichostatin A]; PCB 180 promotes the reaction [leptomycin B results in increased expression of TP53 protein]; Pravastatin inhibits the reaction [leptomycin B results in decreased degradation of TP53 protein]; TP53 gene mutant form inhibits the reaction [leptomycin B results in decreased expression of BIRC5 protein]; TP53 gene mutant form inhibits the reaction [leptomycin B results in increased expression of CDKN1A protein] TP53 gene mutant form results in increased susceptibility to leptomycin B alpha-naphthoflavone inhibits the reaction [Tetrachlorodibenzodioxin inhibits the reaction [leptomycin B results in increased expression of TP53 protein]]; Tetrachlorodibenzodioxin inhibits the reaction [leptomycin B results in increased expression of TP53 protein] leptomycin B affects the expression of TP53 protein
[leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of TP63 mRNA leptomycin B results in decreased expression of TP63 mRNA
leptomycin B results in increased expression of TXNDC5 mRNA 1,1-bis(3'-indolyl)-1-(4-hydroxyphenyl)methane inhibits the reaction [leptomycin B results in increased expression of TXNDC5 mRNA]
leptomycin B results in decreased activity of XPO1 protein [leptomycin B results in decreased activity of XPO1 protein] which results in decreased export of SMAD4 protein
leptomycin B inhibits the reaction [arsenite inhibits the reaction [XPO4 protein results in increased export of SMAD2 protein]]; leptomycin B inhibits the reaction [arsenite inhibits the reaction [XPO4 protein results in increased export of SMAD3 protein]]; leptomycin B inhibits the reaction [monomethylarsonous acid inhibits the reaction [XPO4 protein results in increased export of SMAD2 protein]]; leptomycin B inhibits the reaction [monomethylarsonous acid inhibits the reaction [XPO4 protein results in increased export of SMAD3 protein]]
cyclohexene inhibits the reaction [LTA4H protein results in increased hydrolysis of Leukotriene A4]; Oxygen inhibits the reaction [LTA4H protein results in increased hydrolysis of Leukotriene A4]; Piperonyl Butoxide inhibits the reaction [LTA4H protein results in increased hydrolysis of Leukotriene A4]; propanethiol inhibits the reaction [LTA4H protein results in increased hydrolysis of Leukotriene A4]
ALOX5 protein results in increased secretion of Leukotriene B4 ALOX5 protein results in increased chemical synthesis of Leukotriene B4 [benoxaprofen results in decreased activity of ALOX5 protein] which results in decreased chemical synthesis of Leukotriene B4; [Hydrogen Peroxide results in increased activity of ALOX5 protein] which results in increased chemical synthesis of Leukotriene B4; [Masoprocol results in decreased activity of ALOX5 protein] which results in decreased chemical synthesis of Leukotriene B4; [RS 43179 results in decreased activity of ALOX5 protein] which results in decreased chemical synthesis of Leukotriene B4; [Tamoxifen results in increased expression of ALOX5 protein] which results in increased abundance of Leukotriene B4; [tenidap results in decreased activity of ALOX5 protein] which results in decreased chemical synthesis of Leukotriene B4; [zileuton results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene B4; ALOX5 protein promotes the reaction [lipopolysaccharide, E. coli O26-B6 results in increased abundance of Leukotriene B4]; ALOX5 protein results in increased susceptibility to [Histamine results in increased abundance of Leukotriene B4]; kaempferol inhibits the reaction [ALOX5 protein results in increased chemical synthesis of Leukotriene B4]; Luteolin inhibits the reaction [ALOX5 protein results in increased chemical synthesis of Leukotriene B4]; quercetin 3'-sulfate inhibits the reaction [ALOX5 protein results in increased chemical synthesis of Leukotriene B4]; quercetin 3-O-glucuronide inhibits the reaction [ALOX5 protein results in increased chemical synthesis of Leukotriene B4]; Quercetin inhibits the reaction [ALOX5 protein results in increased chemical synthesis of Leukotriene B4]; Resveratrol inhibits the reaction [[Hydrogen Peroxide results in increased activity of ALOX5 protein] which results in increased chemical synthesis of Leukotriene B4]; zileuton inhibits the reaction [ALOX5 protein promotes the reaction [lipopolysaccharide, E. coli O26-B6 results in increased abundance of Leukotriene B4]]; zileuton inhibits the reaction [ALOX5 protein results in increased susceptibility to [Histamine results in increased abundance of Leukotriene B4]] [[A 78773 co-treated with Calcimycin] results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene B4; [[CMI 392 co-treated with Calcimycin] results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene B4; [[zileuton co-treated with Calcimycin] results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene B4; [Calcimycin results in increased activity of and results in increased localization of ALOX5 protein] which results in increased abundance of Leukotriene B4; [lipopolysaccharide, Escherichia coli O111 B4 results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene B4; [tepoxalin results in decreased activity of ALOX5 protein] inhibits the reaction [Indomethacin results in increased abundance of Leukotriene B4]; [troglitazone results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene B4; [zileuton results in decreased activity of ALOX5 protein] inhibits the reaction [Calcimycin results in increased abundance of Leukotriene B4]; [zileuton results in decreased activity of ALOX5 protein] inhibits the reaction [Indomethacin results in increased abundance of Leukotriene B4]; [zileuton results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene B4; ALOX5 protein promotes the reaction [CXCL8 protein results in increased abundance of Leukotriene B4]; tetrakis(4-benzoic acid)porphyrin inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene B4] [zileuton results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene B4; ALOX5 protein promotes the reaction [Ovalbumin results in increased abundance of Leukotriene B4]; zileuton inhibits the reaction [ALOX5 protein promotes the reaction [Ovalbumin results in increased abundance of Leukotriene B4]]
ALOX5AP protein results in increased susceptibility to [Histamine results in increased abundance of Leukotriene B4]; L 655238 inhibits the reaction [ALOX5AP protein results in increased susceptibility to [Histamine results in increased abundance of Leukotriene B4]]; MK-886 inhibits the reaction [ALOX5AP protein results in increased susceptibility to [Histamine results in increased abundance of Leukotriene B4]]
Leukotriene B4 results in decreased expression of BAX mRNA; Leukotriene B4 results in decreased expression of BAX protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Leukotriene B4 results in increased expression of BAX protein]; wortmannin inhibits the reaction [Leukotriene B4 results in increased expression of BAX protein]
CCL12 protein results in increased abundance of Leukotriene B4 zileuton inhibits the reaction [CCL12 protein results in increased abundance of Leukotriene B4]
Leukotriene B4 results in increased expression of CCL2 protein zileuton inhibits the reaction [CCL2 protein results in increased abundance of Leukotriene B4]
[Calcimycin co-treated with CCL5 protein] results in increased secretion of Leukotriene B4; Dexamethasone inhibits the reaction [[Calcimycin co-treated with CCL5 protein] results in increased secretion of Leukotriene B4]; Masoprocol inhibits the reaction [[Calcimycin co-treated with CCL5 protein] results in increased secretion of Leukotriene B4]
CXCL1 protein results in increased abundance of Leukotriene B4 zileuton inhibits the reaction [CXCL1 protein results in increased abundance of Leukotriene B4]
[2,3,5-trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone co-treated with Leukotriene B4] results in decreased expression of HSD11B2 protein; [Masoprocol co-treated with Leukotriene B4] results in decreased expression of HSD11B2 protein; Leukotriene B4 inhibits the reaction [2,3,5-trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone results in increased activity of HSD11B2 protein]; Leukotriene B4 inhibits the reaction [Masoprocol results in increased activity of HSD11B2 protein] Leukotriene B4 results in decreased expression of HSD11B2 mRNA Leukotriene B4 results in decreased activity of HSD11B2 protein
[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Leukotriene B4; Mangifera indica extract inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Leukotriene B4]; mangiferin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Leukotriene B4]
IL13 protein results in increased abundance of Leukotriene B4 zileuton inhibits the reaction [IL13 protein results in increased abundance of Leukotriene B4]
IL4 protein inhibits the reaction [Calcimycin results in increased metabolism of Leukotriene B4]; IL4 protein inhibits the reaction [Zymosan affects the metabolism of Leukotriene B4]
Leukotriene B4 results in increased expression of [ITGAM protein binds to ITGB2 protein]; LY 255283 analog inhibits the reaction [Leukotriene B4 results in increased expression of [ITGAM protein binds to ITGB2 protein]]; LY 255283 inhibits the reaction [Leukotriene B4 results in increased expression of [ITGAM protein binds to ITGB2 protein]]; LY 293111 inhibits the reaction [Leukotriene B4 results in increased expression of [ITGAM protein binds to ITGB2 protein]] LTB4 increases expression of ITGAM protein on neutrophils and monocytes
Leukotriene B4 results in increased expression of ITGB2 protein Leukotriene B4 results in increased expression of [ITGAM protein binds to ITGB2 protein]; LY 255283 analog inhibits the reaction [Leukotriene B4 results in increased expression of [ITGAM protein binds to ITGB2 protein]]; LY 255283 inhibits the reaction [Leukotriene B4 results in increased expression of [ITGAM protein binds to ITGB2 protein]]; LY 293111 inhibits the reaction [Leukotriene B4 results in increased expression of [ITGAM protein binds to ITGB2 protein]]
1-(4-(benzothiazol-2-yloxy)benzyl)piperidine-4-carboxylic acid inhibits the reaction [LTA4H protein results in increased chemical synthesis of Leukotriene B4]; cyclohexene inhibits the reaction [LTA4H protein results in increased chemical synthesis of Leukotriene B4]; Oxygen inhibits the reaction [LTA4H protein results in increased chemical synthesis of Leukotriene B4]; Piperonyl Butoxide inhibits the reaction [LTA4H protein results in increased chemical synthesis of Leukotriene B4]; propanethiol inhibits the reaction [LTA4H protein results in increased chemical synthesis of Leukotriene B4]
[SC 41930 binds to and results in decreased activity of LTB4R protein] which results in decreased abundance of Leukotriene B4; Leukotriene B4 binds to and affects the activity of LTB4R1 protein Leukotriene B4 binds to and results in increased activity of LTB4R protein; LY 255283 analog inhibits the reaction [Leukotriene B4 binds to and results in increased activity of LTB4R protein]; LY 255283 inhibits the reaction [Leukotriene B4 binds to and results in increased activity of LTB4R protein]; LY 293111 inhibits the reaction [Leukotriene B4 binds to and results in increased activity of LTB4R protein] LTB4R1 protein affects the susceptibility to Leukotriene B4 Leukotriene B4 analog binds to LTB4R1 protein
Leukotriene B4 results in increased expression of MCL1 mRNA; Leukotriene B4 results in increased expression of MCL1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Leukotriene B4 results in increased expression of MCL1 protein]; wortmannin inhibits the reaction [Leukotriene B4 results in increased expression of MCL1 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Leukotriene B4 results in increased expression of MMP9 protein]; SB 203580 inhibits the reaction [Leukotriene B4 results in increased expression of MMP9 protein]
Leukotriene B4 inhibits the reaction [[Zymosan results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitrites]
PLA2G4A protein promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased metabolism of Leukotriene B4]; PLA2G4A protein promotes the reaction [Zymosan analog results in increased metabolism of Leukotriene B4]
ABCC1 protein affects the transport of Leukotriene C4 [Nimustine results in increased expression of ABCC1 protein] which results in increased transport of Leukotriene C4; Adenosine Triphosphate promotes the reaction [ABCC1 protein affects the transport of Leukotriene C4]; Apigenin inhibits the reaction [ABCC1 protein results in increased uptake of Leukotriene C4]; Bilirubin inhibits the reaction [ABCC1 protein affects the transport of Leukotriene C4]; estradiol-17 beta-glucuronide inhibits the reaction [ABCC1 protein affects the transport of Leukotriene C4]; Genistein affects the reaction [ABCC1 protein results in increased uptake of Leukotriene C4]; Glutathione Disulfide promotes the reaction [Leukotriene C4 analog binds to ABCC1 protein]; Glutathione promotes the reaction [Apigenin inhibits the reaction [ABCC1 protein results in increased uptake of Leukotriene C4]]; Glutathione promotes the reaction [Genistein affects the reaction [ABCC1 protein results in increased uptake of Leukotriene C4]]; Glutathione promotes the reaction [naringenin affects the reaction [ABCC1 protein results in increased uptake of Leukotriene C4]]; kaempferol inhibits the reaction [ABCC1 protein results in increased uptake of Leukotriene C4]; myricetin inhibits the reaction [ABCC1 protein results in increased uptake of Leukotriene C4]; naringenin affects the reaction [ABCC1 protein results in increased uptake of Leukotriene C4]; Quercetin inhibits the reaction [ABCC1 protein results in increased uptake of Leukotriene C4] ABCC1 protein mutant form results in decreased transport of Leukotriene C4
ABCC2 protein modified form results in increased transport of Leukotriene C4 verlukast inhibits the reaction [ABCC2 protein results in increased transport of Leukotriene C4] ABCC2 protein affects the transport of Leukotriene C4
[zileuton results in decreased activity of ALOX5 protein] inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Leukotriene C4]; [zileuton results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene C4 [Calcimycin results in increased activity of and results in increased localization of ALOX5 protein] which results in increased abundance of Leukotriene C4 ALOX5 protein promotes the reaction [Ovalbumin results in increased abundance of Leukotriene C4]; zileuton inhibits the reaction [ALOX5 protein promotes the reaction [Ovalbumin results in increased abundance of Leukotriene C4]]
[2-(4-(quinolin-2-yl-methoxy)phenyl)-2-cyclopentylacetic acid results in decreased activity of ALOX5AP protein] which results in decreased abundance of Leukotriene C4; [MK-886 results in decreased activity of ALOX5AP protein] which results in decreased abundance of Leukotriene C4
CLEC7A protein promotes the reaction [Peptidoglycan results in increased metabolism of Leukotriene C4]; CLEC7A protein promotes the reaction [Zymosan results in increased metabolism of Leukotriene C4]
[Leukotriene C4 binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium; CGP 57698 inhibits the reaction [Leukotriene C4 binds to CYSLTR1 protein]; Leukotriene C4 binds to and results in increased activity of CYSLTR1 protein; MEN91507 inhibits the reaction [Leukotriene C4 binds to CYSLTR1 protein]; pobilukast inhibits the reaction [Leukotriene C4 binds to CYSLTR1 protein]; pranlukast inhibits the reaction [Leukotriene C4 binds to CYSLTR1 protein] CYSLTR1 protein binds to and affects the susceptibility to Leukotriene C4; Leukotriene C4 inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein]
[Leukotriene C4 binds to and results in increased activity of CYSLTR2 protein] which results in increased abundance of Calcium; [Leukotriene C4 results in increased activity of CYSLTR2 protein] which results in increased abundance of Calcium; Leukotriene C4 binds to and results in increased activity of CYSLTR2 protein
Leukotriene C4 results in increased expression of EDN1 mRNA; Leukotriene C4 results in increased expression of EDN1 protein zafirlukast inhibits the reaction [Leukotriene C4 results in increased expression of EDN1 mRNA]; zafirlukast inhibits the reaction [Leukotriene C4 results in increased expression of EDN1 protein]
[Beclomethasone results in increased activity of GGT5 protein] which results in increased metabolism of Leukotriene C4; [Fluticasone results in increased activity of GGT5 protein] which results in increased metabolism of Leukotriene C4
Leukotriene C4 results in increased expression of IL13 mRNA [IL13 protein results in increased abundance of Leukotriene C4] which results in increased secretion of MUC5AC protein
Leukotriene C4 binds to and results in decreased activity of MGST1 protein; Leukotriene C4 inhibits the reaction [Glutathione binds to and results in increased activity of MGST1 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Leukotriene C4 results in increased expression of MMP9 protein]; SB 203580 inhibits the reaction [Leukotriene C4 results in increased expression of MMP9 protein]
Leukotriene C4 results in increased expression of MUC5AC mRNA; Leukotriene C4 results in increased expression of MUC5AC protein [IL13 protein results in increased abundance of Leukotriene C4] which results in increased secretion of MUC5AC protein
Leukotriene C4 inhibits the reaction [[Zymosan results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitrites]
PLA2G5 protein promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Leukotriene C4] PLA2G5 protein promotes the reaction [Zymosan results in increased metabolism of Leukotriene C4]
Adenosine Triphosphate promotes the reaction [RALBP1 protein affects the transport of Leukotriene C4]; Colchicine inhibits the reaction [RALBP1 protein affects the transport of Leukotriene C4]
SYK protein promotes the reaction [Peptidoglycan results in increased metabolism of Leukotriene C4]; SYK protein promotes the reaction [Zymosan results in increased metabolism of Leukotriene C4]
ALOX5 protein results in increased abundance of Leukotriene D4 ALOX5 protein promotes the reaction [Ovalbumin results in increased abundance of Leukotriene D4]; zileuton inhibits the reaction [ALOX5 protein promotes the reaction [Ovalbumin results in increased abundance of Leukotriene D4]] [zileuton results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene D4
[Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium; [Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium; [Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased expression of CXCL8 protein; [Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased expression of IL6 protein; [Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased expression of TNF protein; alpha-pentyl-3-(2-quinolinylmethoxy)benzenemethanol inhibits the reaction [Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein]; BAY u9773 inhibits the reaction [[Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium]; BAY u9773 inhibits the reaction [Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein]; BAY u9773 inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein]; CGP 57698 inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein]; CYSLTR1 protein promotes the reaction [Leukotriene D4 results in increased abundance of Calcium]; iralukast inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein]; Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein; LY 171883 inhibits the reaction [Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein]; MEN91507 inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein]; montelukast inhibits the reaction [[Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium]; montelukast inhibits the reaction [Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein]; montelukast inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein]; pobilukast inhibits the reaction [[Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium]; pobilukast inhibits the reaction [Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein]; pobilukast inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein]; pranlukast inhibits the reaction [[Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium]; pranlukast inhibits the reaction [CYSLTR1 protein results in increased susceptibility to Leukotriene D4]; pranlukast inhibits the reaction [Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein]; pranlukast inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein]; verlukast inhibits the reaction [[Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium]; verlukast inhibits the reaction [Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein]; verlukast inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein]; zafirlukast inhibits the reaction [[Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium]; zafirlukast inhibits the reaction [[Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased expression of CXCL8 protein]; zafirlukast inhibits the reaction [[Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased expression of IL6 protein]; zafirlukast inhibits the reaction [[Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased expression of TNF protein]; zafirlukast inhibits the reaction [CYSLTR1 protein promotes the reaction [Leukotriene D4 results in increased abundance of Calcium]]; zafirlukast inhibits the reaction [CYSLTR1 protein results in increased susceptibility to Leukotriene D4]; zafirlukast inhibits the reaction [Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein]; zafirlukast inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein] [Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium; CYSLTR1 protein binds to and affects the susceptibility to Leukotriene D4; Leukotriene C4 inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein]; Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein; Leukotriene E4 inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein]; pranlukast inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein]; verlukast inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein]; zafirlukast inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein]
[Leukotriene D4 binds to and results in increased activity of CYSLTR2 protein] which results in increased abundance of Calcium; [Leukotriene D4 binds to and results in increased activity of CYSLTR2 protein] which results in increased chemical synthesis of inositol 1-phosphate; [Leukotriene D4 results in increased activity of CYSLTR2 protein] which results in increased abundance of Calcium; BAY u9773 inhibits the reaction [[Leukotriene D4 binds to and results in increased activity of CYSLTR2 protein] which results in increased abundance of Calcium]; Leukotriene D4 binds to and results in increased activity of CYSLTR2 protein; Leukotriene D4 promotes the reaction [CYSLTR2 protein binds to ARRB1 protein]; Leukotriene D4 promotes the reaction [CYSLTR2 protein binds to ARRB2 protein]; montelukast inhibits the reaction [Leukotriene D4 binds to CYSLTR2 protein]; pranlukast inhibits the reaction [Leukotriene D4 binds to CYSLTR2 protein]; verlukast inhibits the reaction [Leukotriene D4 binds to CYSLTR2 protein]; zafirlukast inhibits the reaction [Leukotriene D4 binds to CYSLTR2 protein]
Leukotriene D4 results in increased activity of GPR17 protein montelukast inhibits the reaction [Leukotriene D4 results in increased activity of GPR17 protein]
BAY u9773 inhibits the reaction [Leukotriene D4 results in increased secretion of [IL12A protein binds to IL12B protein]]; Leukotriene D4 results in increased secretion of [IL12A protein binds to IL12B protein]; montelukast inhibits the reaction [Leukotriene D4 results in increased secretion of [IL12A protein binds to IL12B protein]]; zileuton inhibits the reaction [Leukotriene D4 results in increased secretion of [IL12A protein binds to IL12B protein]]
BAY u9773 inhibits the reaction [Leukotriene D4 results in increased secretion of [IL12A protein binds to IL12B protein]]; Leukotriene D4 results in increased secretion of [IL12A protein binds to IL12B protein]; montelukast inhibits the reaction [Leukotriene D4 results in increased secretion of [IL12A protein binds to IL12B protein]]; zileuton inhibits the reaction [Leukotriene D4 results in increased secretion of [IL12A protein binds to IL12B protein]]
IL13 protein results in increased abundance of Leukotriene D4 [IL13 protein results in increased abundance of Leukotriene D4] which results in increased secretion of MUC5AC protein
[Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased expression of IL6 protein; BAY u9773 inhibits the reaction [Leukotriene D4 results in increased secretion of IL6 protein]; montelukast inhibits the reaction [Leukotriene D4 results in increased secretion of IL6 protein]; zafirlukast inhibits the reaction [[Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased expression of IL6 protein]; zileuton inhibits the reaction [Leukotriene D4 results in increased secretion of IL6 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Leukotriene D4 results in increased expression of MMP9 protein]; SB 203580 inhibits the reaction [Leukotriene D4 results in increased expression of MMP9 protein]
[IL13 protein results in increased abundance of Leukotriene D4] which results in increased secretion of MUC5AC protein; verlukast inhibits the reaction [Leukotriene D4 results in increased expression of MUC5AC mRNA]; verlukast inhibits the reaction [Leukotriene D4 results in increased expression of MUC5AC protein] Leukotriene D4 results in increased expression of MUC5AC mRNA; Leukotriene D4 results in increased expression of MUC5AC protein
6,7-dimethoxy-3-phenylquinoxaline inhibits the reaction [Leukotriene D4 results in increased phosphorylation of and results in increased activity of PDGFRB protein]; bisindolylmaleimide I inhibits the reaction [Leukotriene D4 results in increased phosphorylation of and results in increased activity of PDGFRB protein]; Leukotriene D4 promotes the reaction [SRC protein binds to PDGFRB protein]; Leukotriene D4 results in increased phosphorylation of and results in increased activity of PDGFRB protein; lipoxin A4 inhibits the reaction [Leukotriene D4 results in increased activity of PDGFRB protein]; pobilukast inhibits the reaction [Leukotriene D4 results in increased phosphorylation of and results in increased activity of PDGFRB protein]
Leukotriene D4 promotes the reaction [SRC protein binds to PDGFRB protein]; Leukotriene D4 results in increased phosphorylation of and results in increased activity of SRC protein; pobilukast inhibits the reaction [Leukotriene D4 results in increased activity of SRC protein]
Leukotriene D4 promotes the reaction [CSF2 protein results in increased expression of TGFB1 protein]; Leukotriene D4 promotes the reaction [ICAM1 protein results in increased expression of TGFB1 protein]; Leukotriene D4 promotes the reaction [IL5 protein results in increased expression of TGFB1 protein]
[Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased expression of TNF protein; BAY u9773 inhibits the reaction [Leukotriene D4 results in increased secretion of TNF protein]; montelukast inhibits the reaction [Leukotriene D4 results in increased secretion of TNF protein]; zafirlukast inhibits the reaction [[Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased expression of TNF protein]; zileuton inhibits the reaction [Leukotriene D4 results in increased secretion of TNF protein]
ALOX5 protein promotes the reaction [Ovalbumin results in increased abundance of Leukotriene E4]; zileuton inhibits the reaction [ALOX5 protein promotes the reaction [Ovalbumin results in increased abundance of Leukotriene E4]] [zileuton results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene E4
Leukotriene E4 binds to CYSLTR1 protein [Leukotriene E4 binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium; Leukotriene E4 binds to and results in increased activity of CYSLTR1 protein; montelukast inhibits the reaction [Leukotriene E4 binds to and results in increased activity of CYSLTR1 protein]; zafirlukast inhibits the reaction [Leukotriene E4 binds to and results in increased activity of CYSLTR1 protein] Leukotriene E4 inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein]
[Leukotriene E4 binds to and results in increased activity of CYSLTR2 protein] which results in increased abundance of Calcium; [Leukotriene E4 results in increased activity of CYSLTR2 protein] which results in increased abundance of Calcium; Leukotriene E4 binds to and results in increased activity of CYSLTR2 protein
1-Butanol inhibits the reaction [Linoleic Acid inhibits the reaction [ABCA1 protein results in increased export of Cholesterol]]; Linoleic Acid inhibits the reaction [ABCA1 protein results in increased export of Cholesterol]; Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Phospholipids]]; PLD2 protein inhibits the reaction [Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased export of Cholesterol]]]; triacsin C inhibits the reaction [Linoleic Acid inhibits the reaction [ABCA1 protein results in increased transport of Cholesterol]]; triacsin C inhibits the reaction [Linoleic Acid inhibits the reaction [ABCA1 protein results in increased transport of Phospholipids]]; triacsin C inhibits the reaction [Linoleic Acid results in increased degradation of ABCA1 protein] Linoleic Acid analog results in decreased expression of ABCA1 mRNA Linoleic Acid results in increased expression of ABCA1 mRNA Linoleic Acid inhibits the reaction [27-hydroxycholesterol results in increased expression of ABCA1 mRNA] Linoleic Acid results in increased phosphorylation of ABCA1 protein
AGER protein results in increased susceptibility to [Azoxymethane co-treated with Glucose co-treated with Linoleic Acid]; Glucose promotes the reaction [Linoleic Acid promotes the reaction [Azoxymethane results in increased expression of AGER protein]]; Linoleic Acid promotes the reaction [Azoxymethane results in increased expression of AGER protein]; Linoleic Acid promotes the reaction [Glucose promotes the reaction [Azoxymethane results in increased expression of AGER protein]]; Losartan inhibits the reaction [Glucose promotes the reaction [Linoleic Acid promotes the reaction [Azoxymethane results in increased expression of AGER protein]]]; Losartan inhibits the reaction [Linoleic Acid promotes the reaction [Glucose promotes the reaction [Azoxymethane results in increased expression of AGER protein]]]; Metformin inhibits the reaction [Glucose promotes the reaction [Linoleic Acid promotes the reaction [Azoxymethane results in increased expression of AGER protein]]]; Metformin inhibits the reaction [Linoleic Acid promotes the reaction [Glucose promotes the reaction [Azoxymethane results in increased expression of AGER protein]]]
Linoleic Acid inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to CYP1A1 promoter]]; Linoleic Acid inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to PTGS2 promoter]]
Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Phospholipids]]; PLD2 protein inhibits the reaction [Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased export of Cholesterol]]]
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Linoleic Acid; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Linoleic Acid]
[Linoleic Acid co-treated with Glucose] affects the reaction [Azoxymethane affects the expression of BCL2 protein]; Linoleic Acid affects the reaction [Azoxymethane affects the expression of BCL2 protein]
Linoleic Acid results in increased expression of CAT protein Linoleic Acid inhibits the reaction [amyloid beta-protein (1-42) results in decreased activity of CAT protein]
CNR1 protein affects the reaction [Linoleic Acid results in increased secretion of GCG protein] CNR1 protein affects the susceptibility to Linoleic Acid
[Linoleic Acid co-treated with Testosterone] results in increased expression of FADS2 mRNA FADS2 protein inhibits the reaction [Linoleic Acid results in increased activity of LOX protein] Linoleic Acid results in increased expression of FADS2 mRNA; Linoleic Acid results in increased expression of FADS2 protein
Linoleic Acid results in increased expression of GSTA1 mRNA NFE2L2 protein promotes the reaction [Linoleic Acid results in increased expression of GSTA1 mRNA]
NFE2L2 mRNA promotes the reaction [Linoleic Acid metabolite results in increased expression of HMOX1 mRNA] Linoleic Acid metabolite results in increased expression of HMOX1 mRNA; Linoleic Acid metabolite results in increased expression of HMOX1 protein
Linoleic Acid results in increased expression of IL1B protein Linoleic Acid inhibits the reaction [amyloid beta-protein (1-42) results in increased expression of IL1B mRNA]
Linoleic Acid affects the expression of IL6 protein Linoleic Acid inhibits the reaction [amyloid beta-protein (1-42) results in increased expression of IL6 mRNA] Linoleic Acid results in increased expression of IL6 mRNA Linoleic Acid results in increased secretion of IL6 protein
FADS2 protein inhibits the reaction [Linoleic Acid results in increased activity of LOX protein]; TGFB1 protein promotes the reaction [Linoleic Acid results in increased activity of LOX protein]
Linoleic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of and results in increased activity of MAPK3 protein]
Linoleic Acid results in decreased expression of and results in decreased activity of MMP9 protein [Linoleic Acid co-treated with Glucose] affects the reaction [Azoxymethane affects the expression of MMP9 protein]; Linoleic Acid affects the reaction [Azoxymethane affects the expression of MMP9 protein] Linoleic Acid results in decreased expression of MMP9 mRNA
Linoleic Acid metabolite results in increased expression of NFE2L2 protein; Linoleic Acid results in increased expression of NFE2L2 mRNA; Linoleic Acid results in increased expression of NFE2L2 protein NFE2L2 mRNA promotes the reaction [Linoleic Acid metabolite results in increased expression of HMOX1 mRNA]; NFE2L2 protein promotes the reaction [Linoleic Acid results in increased expression of CYP2A6 mRNA]; NFE2L2 protein promotes the reaction [Linoleic Acid results in increased expression of CYP2A6 protein]; NFE2L2 protein promotes the reaction [Linoleic Acid results in increased expression of GSTA1 mRNA]
[Linoleic Acid co-treated with Glucose] affects the reaction [Azoxymethane affects the expression of NOS2 protein]; Linoleic Acid affects the reaction [Azoxymethane affects the expression of NOS2 protein]
PLD2 protein inhibits the reaction [Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased export of Cholesterol]]]
Linoleic Acid inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon]; Linoleic Acid inhibits the reaction [PON1 protein results in increased hydrolysis of phenylacetic acid] Linoleic Acid results in decreased activity of PON1 protein
[Bezafibrate binds to and results in increased activity of PPARA protein] which results in increased oxidation of Linoleic Acid; Linoleic Acid affects the reaction [PPARA protein binds to CREBBP protein]; Linoleic Acid binds to and results in increased activity of PPARA protein; Linoleic Acid promotes the reaction [PPARA protein binds to NCOA1 protein]; Linoleic Acid promotes the reaction [PPARA protein binds to NCOA2 protein] Linoleic Acid results in increased expression of PPARA mRNA PPARA protein affects the abundance of Linoleic Acid Diethylhexyl Phthalate inhibits the reaction [PPARA protein affects the abundance of Linoleic Acid]; Linoleic Acid binds to and results in increased activity of PPARA protein Linoleic Acid results in increased expression of PPARA mRNA; Linoleic Acid results in increased expression of PPARA protein Linoleic Acid results in increased activity of PPARA protein Linoleic Acid binds to PPARA protein
Linoleic Acid binds to and results in increased activity of PPARB protein Linoleic Acid results in decreased expression of PPARD mRNA Linoleic Acid results in increased expression of PPARD mRNA Linoleic Acid results in increased activity of PPARD protein Linoleic Acid binds to PPARB protein
Linoleic Acid binds to PPARG protein Linoleic Acid binds to and results in increased activity of PPARG protein Linoleic Acid results in increased expression of PPARG mRNA resveratrol inhibits the reaction [Linoleic Acid results in increased expression of PPARG protein] Linoleic Acid results in increased activity of PPARG protein Linoleic Acid results in decreased expression of PPARG mRNA; Linoleic Acid results in decreased expression of PPARG protein
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Linoleic Acid; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Linoleic Acid]
Linoleic Acid results in increased expression of PTGS2 mRNA Linoleic Acid inhibits the reaction [Benzo(a)pyrene results in increased expression of PTGS2 mRNA]; Linoleic Acid inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to PTGS2 promoter]]; Linoleic Acid inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA]
[Linoleic Acid co-treated with Testosterone] results in increased expression of SCD mRNA Linoleic Acid results in increased expression of SCD mRNA; Linoleic Acid results in increased expression of SCD protein
Linoleic Acid results in decreased susceptibility to TNF protein Linoleic Acid inhibits the reaction [amyloid beta-protein (1-42) results in increased expression of TNF mRNA]
lipoxin A4 inhibits the reaction [Ovalbumin results in increased expression of ACTA2 mRNA]; lipoxin A4 inhibits the reaction [Ovalbumin results in increased expression of ACTA2 protein]
2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of AGT protein alternative form]]; 7-Ala-angiotensin (1-7) inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of AGT protein alternative form]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of AGT protein alternative form]]; lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of AGT protein alternative form]
[Aspirin results in increased abundance of lipoxin A4] which results in increased expression of FPR2; lipoxin A4 analog binds to and results in decreased activity of FPR2 protein lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of FPR2 mRNA] lipoxin A4 results in increased activity of FPR2
lipoxin A4 results in increased expression of HMOX1 mRNA; lipoxin A4 results in increased expression of HMOX1 protein lipoxin A4 promotes the reaction [NFE2L2 protein binds to HMOX1 enhancer]
ICAM1 protein affects the susceptibility to lipoxin A4 lipoxin A4 results in increased expression of ICAM1 protein Gentamicins inhibits the reaction [lipoxin A4 results in increased expression of ICAM1 protein]
2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL10 protein]]; 7-Ala-angiotensin (1-7) inhibits the reaction [lipoxin A4 promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL10 protein]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL10 protein]]; lipoxin A4 promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL10 protein]
lipoxin A4 analog results in decreased expression of IL1B protein 2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B protein]]; 7-Ala-angiotensin (1-7) inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B protein]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B protein]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]]; lipoxin A4 analog inhibits the reaction [TNF protein results in increased secretion of IL1B protein]; lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B protein]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein] lipoxin A4 analog results in decreased secretion of IL1B protein lipoxin A4 analog inhibits the reaction [TNF protein results in increased expression of IL1B mRNA]; lipoxin A4 analog inhibits the reaction [TNF protein results in increased secretion of IL1B protein]; lipoxin A4 inhibits the reaction [TNF protein results in increased secretion of IL1B protein]
lipoxin A4 analog results in increased secretion of IL4 protein lipoxin A4 inhibits the reaction [Ovalbumin results in increased expression of IL4 protein]
2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [[lipoxin A4 co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MAS1 mRNA]; 2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of MAS1 protein]]; 7-Ala-angiotensin (1-7) inhibits the reaction [[lipoxin A4 co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MAS1 mRNA]; 7-Ala-angiotensin (1-7) inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of MAS1 protein]]; [lipoxin A4 co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MAS1 mRNA; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [[lipoxin A4 co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MAS1 mRNA]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of MAS1 protein]]; lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of MAS1 protein]
2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased activity of MPO protein]]; 7-Ala-angiotensin (1-7) inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased activity of MPO protein]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased activity of MPO protein]]; lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased activity of MPO protein]
2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased degradation of NFKBIA protein]]; 7-Ala-angiotensin (1-7) inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased degradation of NFKBIA protein]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased degradation of NFKBIA protein]]; lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased degradation of NFKBIA protein]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased degradation of NFKBIA protein]
butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]
lipoxin A4 affects the reaction [PDGFB protein results in increased phosphorylation of PDGFRB protein]; PDGFB protein promotes the reaction [lipoxin A4 results in decreased phosphorylation of PDGFRB protein]
lipoxin A4 affects the reaction [PDGFB protein results in increased phosphorylation of PDGFRB protein]; lipoxin A4 inhibits the reaction [Leukotriene D4 results in increased activity of PDGFRB protein]; PDGFB protein promotes the reaction [lipoxin A4 results in decreased phosphorylation of PDGFRB protein]
[lipoxin A4 co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of PTGS2 protein; Celecoxib inhibits the reaction [PTGS2 protein affects the abundance of lipoxin A4]; lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of PTGS2 protein]
lipoxin A4 inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein] 2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of and affects the localization of RELA protein]]; 7-Ala-angiotensin (1-7) inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of and affects the localization of RELA protein]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of and affects the localization of RELA protein]]; lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of and affects the localization of RELA protein]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased localization of RELA protein]
AHR affects the reaction [lipoxin A4 results in increased expression of SOCS2 mRNA]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 results in increased expression of SOCS2 mRNA] lipoxin A4 results in increased expression of SOCS2 mRNA; lipoxin A4 results in increased expression of SOCS2 protein
lipoxin A4 results in increased expression of TGFB1 protein Gentamicins inhibits the reaction [lipoxin A4 results in increased expression of TGFB1 protein]
lipoxin A4 analog inhibits the reaction [TNF protein results in increased expression of IL1B mRNA]; lipoxin A4 analog inhibits the reaction [TNF protein results in increased secretion of IL1B protein]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; lipoxin A4 inhibits the reaction [TNF protein results in increased secretion of IL1B protein] Gentamicins inhibits the reaction [lipoxin A4 results in increased expression of TNF protein] 2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]]; 7-Ala-angiotensin (1-7) inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]; lipoxin A4 analog inhibits the reaction [TNF protein results in increased secretion of CXCL2 protein]; lipoxin A4 analog inhibits the reaction [TNF protein results in increased secretion of IL1B protein]; lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]
Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [piperine results in increased expression of ABCB1 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [piperine results in increased expression of ABCB1 protein]]; NR1I2 protein promotes the reaction [piperine results in increased expression of ABCB1 mRNA]; NR1I2 protein promotes the reaction [piperine results in increased expression of ABCB1 protein] piperine analog results in decreased expression of ABCB1 protein piperine results in increased expression of ABCB1 mRNA; piperine results in increased expression of ABCB1 protein
piperine inhibits the reaction [beryllium nitrate results in decreased expression of ALB protein]; sodium-4,5-dihydroxy-1,3-benzene disulfonate promotes the reaction [piperine inhibits the reaction [beryllium nitrate results in decreased expression of ALB protein]]
piperine results in increased expression of BAX protein [piperine analog co-treated with Paclitaxel] results in increased expression of BAX protein; piperine inhibits the reaction [Curcumin results in decreased expression of BAX protein]
piperine results in decreased expression of BCL2 protein [piperine analog co-treated with Paclitaxel] results in decreased expression of BCL2 protein; [piperine co-treated with Curcumin] results in decreased expression of BCL2 protein
piperine inhibits the reaction [Cadmium results in increased activity of CASP3 protein] [piperine analog co-treated with Paclitaxel] results in increased cleavage of CASP3 protein; piperine inhibits the reaction [Curcumin results in decreased expression of CASP3 protein] piperine results in increased cleavage of CASP3 protein
[piperine co-treated with NR1I2 protein] results in increased expression of CYP3A4 mRNA; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [piperine results in increased expression of CYP3A4 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [piperine results in increased expression of CYP3A4 protein]]; NR1I2 protein promotes the reaction [piperine results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [piperine results in increased expression of CYP3A4 protein] piperine results in increased expression of CYP3A4 mRNA; piperine results in increased expression of CYP3A4 protein
piperine inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of FOS protein] piperine results in decreased expression of FOS mRNA piperine results in decreased localization of FOS protein
piperine inhibits the reaction [beryllium nitrate results in increased activity of GPT protein]; sodium-4,5-dihydroxy-1,3-benzene disulfonate promotes the reaction [piperine inhibits the reaction [beryllium nitrate results in increased activity of GPT protein]]
[Curcumin co-treated with piperine] results in increased expression of HMOX1 mRNA; [Curcumin co-treated with piperine] results in increased expression of HMOX1 protein; Acetylcysteine inhibits the reaction [[Curcumin co-treated with piperine] results in increased expression of HMOX1 protein] [piperine co-treated with Cimetidine co-treated with Pyruvates] inhibits the reaction [Puromycin Aminonucleoside results in increased expression of HMOX1 protein]
[Curcumin co-treated with piperine] inhibits the reaction [IFNG protein results in increased abundance of Nitrites]; tin protoporphyrin IX inhibits the reaction [[Curcumin co-treated with piperine] inhibits the reaction [IFNG protein results in increased abundance of Nitrites]]
piperine inhibits the reaction [IL2 protein results in increased expression of CCNB1 protein]; piperine inhibits the reaction [IL2 protein results in increased expression of CCND2 protein]; piperine inhibits the reaction [IL2 protein results in increased expression of CDC25C protein]; piperine inhibits the reaction [IL2 protein results in increased expression of CDK1 protein]; piperine inhibits the reaction [IL2 protein results in increased expression of CDK4 protein]; piperine inhibits the reaction [IL2 protein results in increased expression of CDK6 protein]; piperine inhibits the reaction [IL2 protein results in increased phosphorylation of AKT1 protein]; piperine inhibits the reaction [IL2 protein results in increased phosphorylation of MAPK1 protein]; piperine inhibits the reaction [IL2 protein results in increased phosphorylation of MAPK3 protein]; piperine inhibits the reaction [IL2 protein results in increased phosphorylation of STAT3 protein]; piperine inhibits the reaction [IL2 protein results in increased phosphorylation of STAT5A protein]; piperine inhibits the reaction [IL2 protein results in increased phosphorylation of STAT5B protein]
piperine inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of JUN protein]; piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of JUN protein]
piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK1 protein] piperine inhibits the reaction [IL2 protein results in increased phosphorylation of MAPK1 protein]; piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK1 protein]
piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK3 protein] piperine inhibits the reaction [IL2 protein results in increased phosphorylation of MAPK3 protein]; piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK3 protein]
piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP14 mRNA]; piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP14 protein]
piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 mRNA]; piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 protein] piperine results in decreased expression of MMP9 protein
Ketoconazole inhibits the reaction [piperine promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; piperine promotes the reaction [NCOA1 protein binds to NR1I2 protein]
piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased degradation of NFKBIA protein] piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of and results in increased degradation of NFKBIA protein]
[piperine co-treated with NR1I2 protein] results in increased expression of CYP3A4 mRNA; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [piperine results in increased expression of ABCB1 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [piperine results in increased expression of ABCB1 protein]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [piperine results in increased expression of CYP3A4 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [piperine results in increased expression of CYP3A4 protein]]; Ketoconazole inhibits the reaction [piperine promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; NR1I2 protein promotes the reaction [piperine results in increased expression of ABCB1 mRNA]; NR1I2 protein promotes the reaction [piperine results in increased expression of ABCB1 protein]; NR1I2 protein promotes the reaction [piperine results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [piperine results in increased expression of CYP3A4 protein]; piperine promotes the reaction [NCOA1 protein binds to NR1I2 protein] piperine results in increased expression of NR1I2 protein piperine results in increased activity of NR1I2 protein piperine binds to NR1I2 protein
piperine inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [PTGS2 protein results in increased chemical synthesis of Dinoprostone]]; piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of PTGS2 protein]; piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 mRNA]; piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein]
piperine inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of RELA protein]; piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of RELA protein] piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of and affects the localization of RELA protein] piperine results in decreased localization of RELA protein
[piperine co-treated with Cimetidine co-treated with Pyruvates] inhibits the reaction [Puromycin Aminonucleoside results in decreased expression of SLC9A3 protein]
resolvin D1 inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]; t-butyloxycarbonyl-methionyl-leucyl-phenylalanine inhibits the reaction [resolvin D1 inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]]
resolvin D1 analog inhibits the reaction [Paraquat results in decreased expression of HMOX1 mRNA]; resolvin D1 inhibits the reaction [Paraquat results in decreased expression of HMOX1 mRNA]
resolvin D1 inhibits the reaction [Lipopolysaccharides results in increased secretion of IFNG protein]; t-butyloxycarbonyl-methionyl-leucyl-phenylalanine inhibits the reaction [resolvin D1 inhibits the reaction [Lipopolysaccharides results in increased secretion of IFNG protein]]
resolvin D1 analog inhibits the reaction [Paraquat results in increased expression of IL1B protein]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]
resolvin D1 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; t-butyloxycarbonyl-methionyl-leucyl-phenylalanine inhibits the reaction [resolvin D1 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]]
resolvin D1 analog inhibits the reaction [Paraquat results in increased activity of MPO protein]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; resolvin D1 inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein]
resolvin D1 analog inhibits the reaction [Paraquat affects the localization of NFE2L2 protein]; resolvin D1 inhibits the reaction [Paraquat affects the localization of NFE2L2 protein]; resolvin D1 inhibits the reaction [Paraquat results in decreased expression of NFE2L2 mRNA] resolvin D1 inhibits the reaction [Cadmium Chloride results in increased activity of NFE2L2 protein]; resolvin D1 inhibits the reaction [Cadmium Chloride results in increased expression of and results in increased activity of NFE2L2 protein]
resolvin D1 analog inhibits the reaction [Paraquat results in increased phosphorylation of RELA protein]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased activity of RELA protein] resolvin D1 inhibits the reaction [Cadmium Chloride results in increased expression of RELA protein]
resolvin D1 analog inhibits the reaction [Paraquat results in increased expression of TNF protein]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; resolvin D1 inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; t-butyloxycarbonyl-methionyl-leucyl-phenylalanine inhibits the reaction [resolvin D1 inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]
resolvin D2 inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; resolvin D2 inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein]
resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; resolvin D2 inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]
Soybean Oil promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GSTP1 mRNA]; Soybean Oil promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GSTP1 protein]
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of tetracosapentaenoic acid; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of tetracosapentaenoic acid]
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of tetracosapentaenoic acid; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of tetracosapentaenoic acid]
browse the term
